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Abstract 
 
The discovery of CRISPR has revolutionized the study of life by providing tools for the precise 
and controlled manipulation of an organisms’ genome. Knocking out, suppressing, enhancing, or 
replacing select genes using CRISPR have revealed their unique contributions to an organisms’ 
survival with an ease that was unachievable with the prior state-of-the-art methods. This 
innovation has extended to whole-genome screening, previously conducted with small hairpin 
RNA (shRNA) libraries. CRISPR-Cas9 pooled library screens have been shown to effectively 
identify genes essential to a number of physiological processes including drug toxicity and viral 
infection. Herein, we used previously designed CRISPR-Cas9 knockout libraries to perform 
whole genome screens on cells subjected to oxidative stress to discovery previously unidentified 
genes that provide protection under these conditions. Conducting these screens revealed 
previously identified essential genes in the untreated population in accordance with our 
expectations. Performing the screens in cell populations under oxidative stress revealed several 
individual genes with putative roles associated with or accessory to stress tolerance but failed to 
yield a uniform collection of genes clearly identifiable with this physiological response.  
 Recent efforts to improve upon existing CRISPR methods have centered around using the 
related Cpf1 nuclease. Cpf1 offers several advantages over Cas9, the most important being its 
ability to process multiple targeting RNAs from a single expression vector and enabling the 
simultaneous knockout of multiple genes. With this in mind, we designed randomized duplex 
 xiii 
Cpf1 libraries targeted to the DHHC-family palmitoyltransferases (PAT). The DHHC PATs 
constitute a large family of structurally related protein acyltransferases for which substrates and 
the rules that dictate their specification are still largely unknown. These Cpf1 libraries were then 
used in growth screens with the hope of determining to what extent, if any, that functional 
redundancy existed in the substrate profiles of DHHC PATs. Initial screens using these libraries 
revealed no identifiable change in cell growth for any combination of DHHCs. This was also the 
case for the included essential gene controls, indicating that inefficiency in Cpf1 activity was to 
blame for the apparent lack of discernable hits generated by the screen. This result was supported 
by recent literature that found that unmodified Cpf1 significantly underperformed Cas9 when 
used to perform pooled screens.  
 Although our work with Cas9 and Cpf1 CRISPR screens did not yield the results desired 
at the outset of this work they did provide us with several considerations that may serve as useful 
guidelines for others who wish to make use of these powerful genetic tools. 
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Chapter 1  
 
 
Introduction 
 
Genomic Editing and Screening: Past, Present, and Future 
 
1.1 Early Genome Editing and Its Limitations 
 
The discovery of the DNA double helix led in short order to a search for methods to manipulate 
its sequence. The discovery of DNA repair and recombination provided inspiration for the first 
successful demonstrations of selective editing of the DNA sequence.1 These made use of 
complementary sequences between the targeted region of the genome and an exogenous donor 
plasmid to drive homologous recombination between them and stably introduce selective 
modifications to the genome.2,3 The efficacy of these methods was later improved upon by 
introducing precise breaks in the DNA at desired locations within the genome using chemical or 
cross-linking agents.4,5(Figure 1) 
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Figure 1. Early targeted genome editing made possible thorough the introduction of synthetic 
template oligonucleotides was improved by the concurrent introduction of complementary triple-
helical DNA modified with a crosslinking agent to induce double stranded breaks in the genome.  
 
However, even with these improvements the prevalence of the desired genomic modifications 
hardly ever approached 1.0 percent of the subject population, rendering them impracticable for 
anything more than the simplest investigations.6,7 The discovery of first zinc finger nucleases 
(ZNFs) and then transcriptional activator-like effector nucleases (TALENs) offered the 
possibility of improvement over these early methods by providing greater specificity and 
flexibility in the selection of genomic targets.8 These methods combined the DNA-binding 
domains of zinc finger and transcriptional activator-like effector proteins with the nonspecific 
nuclease domain of the FokI restriction endonuclease to produce a synthetic targeted 
endonuclease capable of editing specific regions of the genome.9,10 A feature critical to the  
specificity of these nucleases is the requirement that the FokI domain dimerize to enable cutting 
of the DNA, necessitating the design of two unique DNA binding domains for each genomic 
target.11(Figure 2)  
Cross-linking Reagent
Homologous
Recombination
Donor Strand
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Figure 2. ZNFs (top) and TALENs (bottom) are engineered fusions of zinc finger and 
transcription activator like effector DNA binding and FokI nuclease domains. Pairs of ZNFs and 
TALENs are designed to recognize specific regions of the genome and induce double-stranded 
breaks upon dimerization of the FokI domains. 
 
This has been shown to permit controlled editing of the genome with minimal risk of off-target 
effects and demonstrably improved editing efficiency over earlier methods.12 However, in spite 
of these advantages ZNFs and TALENs have only seen limited use due to the inherent 
difficulties of designing and validating heterodimeric pairs for every DNA locus of interest.13 
RNA-mediated gene silencing provides an alternative approach to addressing the challenge of 
controlling gene expression. Whether introduced directly as double-stranded small interfering 
RNAs (siRNAs) or through expression vectors as small hairpin RNAs (shRNAs) these small 
RNAs operate to control gene expression through fundamentally different mechanisms to those 
that operate at the level of the genome and, in doing so, address many of their inherent 
shortcomings. RNA silencing suppresses gene expression by targeting and degrading mRNA 
transcribed from the genome rather than the genome itself, making its effects reversible and far 
more amenable to the study of genes that would otherwise be lethal if permanently depleted by 
Zinc Finger
Domain
Zinc Finger
Domain
FokI Domain
FokI Domain
5’ 3’
3’ 5’
TALE Domain
FokI Domain
FokI Domain
5’ 3’
3’ 5’
TALE Domain
DSB
DSB
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gene knockout.14 Furthermore, because RNA silencing operates on the basis of nucleotide 
sequence complementarity it can be easily scaled to suppress the expression of any number of 
genes desired even to the level of the genome.15(Figure 3)  
 
 
Figure 3. Targeted suppression of gene expression by the stable introduction of shRNA 
expression vectors. 
 
This flexibility made possible the first global investigations of gene function using shRNA 
expression libraries targeting large numbers of known protein-coding genes.16 Pooled screens 
performed with these libraries led to the identification of genes critical to cellular function17,18, 
drug action19, and viral pathogenesis20 among other biological phenomena. Whatever advantages 
RNA silencing held over nuclease-dependent methods of gene editing in scalability it lacked in 
efficiency and specificity. Different sequences used to induce RNA silencing would often result 
in variable levels of suppression with sometimes even the minimal levels of expression being 
Transcription mRNA
shRNA Expression
Vector
Genomic DNA
Nucleus
Cytoplasm
Pre-shRNA
Dicer
RISC
Degraded mRNA
Mature 
shRNA
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sufficient to maintain a detectably normal phenotype.21 Furthermore, it was hardly uncommon 
for sequences targeted to one particular gene to exert unintended but measurable effects on 
others, thereby confounding the interpretation of results.22 To this point the genetic tools that had 
been developed provided a means, although imperfect, to interpret gene function although an 
ideal system of gene editing, one that combined the scalability and flexibility of RNA silencing 
with the efficiency and specificity of engineered nucleases remained out of reach. 
 
1.2 The Emergence of CRISPR-Cas9 Gene Editing 
Since its discovery in S. thermophilus23 and subsequent demonstration as a gene-editing tool in 
species other than bacteria24, the CRISPR-Cas9 system has been elaborated into a versatile set of 
tools for specific gene editing in organisms spanning all domains of life. Cas9 is a non-specific 
nuclease that, once combined with short guide RNAs (crRNAs), localizes to complementary 
regions within the genome, creates double-stranded breaks around the target sequence, and 
removes it from the genome.25(Figure 4) Once synthesized, pre-crRNAs containing a targeting 
sequence interact with a complementary trans-activating RNA to form a mature guide RNA 
(sgRNA) that is recognized by Cas9 and then subsequently directs it to complementary regions 
within the genome, recognizing a 20bp sequence proximal to a short, protospacer adjacent motif 
(PAM)  (5’-NGG-3’ for the often used spCas9).26 To repair the double-stranded break, cells 
generally rely on the more efficient but error-prone nonhomologous end-joining (NHEJ), 
resulting in inactivating mutations when the Cas9 nuclease is targeted to protein-coding regions 
of the genome.27 Since Cas9 only generates inactivating mutations it avoids any issues with 
incomplete suppression of gene expression that plague siRNA-mediated knockdown. 
Furthermore, Cas9 has been shown to exhibit low off-target effects28 and so when applied in a 
pooled screen format similar to that used for shRNAs provides a more unambiguous 
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determination of gene function at the level of the genome for any process under investigation. 
Traditional Cas9 knockout methods have also been modified for genome screening by 
transcriptional inhibition or activation of target genes using inactivated Cas9 (dCas9) 
activator/repressor fusions29,30,31, providing a versatile platform for performing genome-wide 
screens. These methods together have been used in support or in place of shRNA-based screens 
to identify previously unknown essential genes32,33,34, oncogenes35, mediators of viral 
replication36,37, and drug action38. 
 
 
 
Figure 4. Mechanism of action of CRISPR-Cas9. crRNAs combine with tracrRNA in the native 
CRISPR system to form mature sgRNAs. These are recognized through the stem-loop structure 
of the tracrRNA by the Cas9 nuclease which is then directed to its genomic target by the 
complementary 20bp sequence of the crRNA where it creates a double stranded break in the 
DNA. 
cas9cas1cas2csn2
CRISPR array tracrRNA
pre-crRNA tracrRNA
Cas9
Cas9
 7 
 
1.3 Cpf1: The Next Generation of CRISPR Gene Editing 
A recent addition to the growing number of known CRISPR-Cas systems, Cpf1 was discovered 
to be a type II system similar in make to Cas9, composed of a single large Cas effector protein 
and relying on complementary crRNAs to mediate genetic interference.39 There are, however, 
several functional differences that distinguish Cpf1 from its better known relative. Unlike Cas9 
systems, Cpf1 crRNAs do not require a trans-activating crRNA (tracrRNA) to process CRISPR 
arrays into mature crRNAs.40 Cpf1 also recognizes and cleaves DNA sequences preceded by a T-
rich (TTTN) protospacer-adjacent motif (PAM) and generates a staggered double-stranded break 
in the DNA outside of the target sequence as opposed to the blunt-end cut internal to target 
sequence produced by Cas9.41 These functional differences consequently lend several advantages 
to Cpf1 over Cas9 when used for targeted gene editing. Chief among these is the ability of Cpf1 
to process its own mature crRNAs without assistance from endogenous cellular components.42 
This allows for multiple crRNAs to be expressed from a single Pol III promoter and creates 
opportunities for exploring multiplex gene editing and screening whereas previously this only 
possible by either expressing single crRNAs from multiple promoters or simultaneous use of 
multiple plasmids with Cas9.43(Figure 5) Cpf1 has also been shown to cleave DNA distal to the 
target site , promoting the formation of indels there and preserving the target site for additional 
rounds of cleavage.40 Moreover, the ability of Cpf1 to carry out gene editing from these arrays 
has been demonstrated across multiple genetic models including animals and plants.44The utility 
of these unique attributes was recently demonstrated by using Cpf1 to conduct randomized 
duplex genetic knockout screens, all the while leaving open the possibility of carrying out similar 
screens of higher multiplicity; something that was previously unachievable with Cas9.45 
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Figure 5. Processing of crRNAs by Cpf1. Unlike Cas9, Cpf1 does not require a tracrRNA to 
bind to its crRNAs and is capable of processing multiple crRNAs from a single continuous 
transcript. 
 
1.4 Summary and Outlook     
 
The advantages of CRISPR-based genomic screens over preceding methods have been 
repeatedly demonstrated since their introduction. The following chapters detail our efforts to 
harness the unmatched flexibility and accuracy of CRISPR genomic screens to gain greater 
insight into complex biological phenomena.  
In Chapter 2, we detail our attempt the use a whole genome CRISPR-Cas9 screen to 
identify critical components of the oxidative stress response. Here, limitations in the design of 
the screen with regard to the application of genotoxic stress prevented the identification of our 
intended gene targets, demonstrating the importance proper design and validation in the 
performance of these genomic screens. 
gRNA 1 gRNA 2Repeat Repeat
Cpf1
 CRISPR-Cpf1 
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In Chapter 3, we go over our endeavors to design and apply a novel CRISPR-Cpf1 
duplex knockout library to investigate questions of functional within a family of protein 
acyltransferases. Here, previously unknown functional limitations of CRISPR-Cpf1prevented us 
from accomplishing our stated experimental objectives but do provide valuable insight into the 
use of this system for future endeavors.   
 In Chapter 4, we summarize our experimental outcomes and use them to evaluate the 
limitations of CRISPR genomic screening. We then provide recommendations on the use of 
CRISPR-based methods in future work on the basis of these and recently published literature.  
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Chapter 2 
Investigating Cellular Oxidative Stress using CRISPR-Cas9 Genomic Screens 
 
1.1 Introduction 
1.1.1 Oxidative Stress and Cellular Life 
Reactive small molecules produced as the byproducts of normal metabolism are a feature of all 
cellular life. These reactive oxygen species (ROS) have the potential to cause severe dysfunction 
if left unchecked by the cell.46,47 This led early on in the history of life to the evolution of stress 
responses to mitigate the deleterious effects of these metabolic byproducts.48 The components of 
these stress responses can be found in some form in all of life, ranging from simple antioxidative 
enzymes of bacteria and archaea to the elaborate networks found in multicellular organisms.49 
The sheer genomic complexity of higher organisms complicates the identification of genes 
involved in these stress responses and their individual contributions to preventing cellular 
damage. A further impediment to understanding these genes play centers around the essential 
role that these reactive small molecules play in normal cellular signaling. Normal cellular 
function therefore requires that a balance be maintained between their beneficial aspects and the 
damage that they will inevitably cause if left unchecked.50 The overall redox balance of the cell 
is maintained through active and passive mechanisms by an interrelated group of proteins. These 
include the peroxiredoxins, superoxide dismutase, and catalase which catalyze the conversion of 
ROS into less reactive forms, thioredoxins which are responsible for reducing cysteine residues 
that have been oxidized by ROS, and glutathione/glutaredoxin which function as a buffer to the 
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rest of the cell by scavenging free ROS.51 Effective signaling via ROS requires a localized 
disruption of this imbalance while maintaining the overall redox state of the cell. These localized 
oxidative bursts may be caused by the environment or by endogenous sources such as NADPH-
oxidase or nitric oxide synthase. The sudden increase in ROS overwhelms the localized buffering 
capacity of antioxidative enzymes and permits oxidation of cysteine residues.52 Depending on 
the local concentration of ROS, the thiol groups of cysteine residues may be oxidized 
sequentially to form sulfenic, sulfinic, and sulfonic acids respectively.53(Figure 6) Of these only 
the short-lived sulfenic and more stable sulfinic acid modifications can be reversed.54 Oxidation 
of cysteine residues to any of these species has been shown to alter protein function either 
directly by altering the structure of the target protein or indirectly by blocking alternative post-
translational modifications (PTMs) such as phosphorylation.52,55 Such alterations may be 
activating or deactivating depending on the protein in question and may influence signal 
transduction by altering enzymatic activity, localization, and/or protein-protein interactions.54 
The unique chemistry of these cysteine oxoforms has led to the development of selective 
molecular probes that can be used to identify proteins containing these modifications.56 These 
probes have led to the identification of a number of proteins containing oxidized cysteine 
residues with functions ranging from signal transduction, redox homeostasis, and metabolism to 
DNA repair.57 Given the central importance of ROS to normal cellular function it may be 
presumed that there are yet many other proteins that play a part or are influenced by oxidative 
stress that have yet to be identified. The role that these proteins are known to play in pathological 
states such as cancer, neurodegeneration, and ageing necessitate that further efforts be made to 
identify all proteins that play a role in modulating oxidative stress.   
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Figure 6. Sequential oxidation of cysteine by reactive oxygen species modulates protein activity. 
 
1.2 Research Justification and Objectives 
Previous efforts to identify the components of the cellular oxidative stress response using small 
molecule probes have revealed a large number of proteins spanning a range of functional classes 
with many as yet to be identified. To date, only limited efforts have been made to fully 
characterize the components of the cellular oxidative stress response using modern genomic 
screening methods. Previous attempts to accomplish this relied on sub-optimal screening 
methods using libraries that provided only partial genomic coverage58,59. We therefore 
hypothesize that there exist numerous genes that have yet to be implicated in the cellular 
oxidative stress response. CRISPR-Cas9 pooled knockout libraries currently represent the state-
of-the-art in genomic screening. Using a validated whole-genome CRISPR library (Toronto 
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Knockout Library33) we will attempt to identify the genes involved in maintaining cellular redox 
homeostasis. (Scheme 1) We anticipate finding multiple genes, both characterized and 
uncharacterized, that have never been implicated in oxidative stress. By identifying these 
proteins and determining their roles in redox homeostasis we hope to arrive at a new 
understanding of oxidative stress and the factors that lead to abnormal function and the creation 
of disease states such as those seen in cancer and neurodegeneration. 
 
Scheme 1. Diagrammatic representation of methods used for screening of oxidative stress factors 
by CRISPR knockout screening. 
 
1.3 Methodology 
1.3.1 Cell Culture 
HAP1 cells were obtained from the laboratory of G. Van der Goot (Ecole Polytechnique 
Fédérale de Lausanne) and cultured in Iscove’s Modified Dulbecco’s Medium (Gibco) 
supplemented with 10% v/v Fetal Bovine Serum (HyClone) and 1% v/v penicillin/streptomycin 
Transduce with lentiviral 
genome wide gRNA library
Select for cells carrying 
gRNA insert and amplify Induce Cas9 expression
H2O2
Treat with medium + H2O2Treat with medium - H2O2
Isolate genomic DNA
PCR amplify, attach adaptors/barcodes,
pool, and sequence
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(Gibco). HEK293T cell lines were maintained Dulbecco’s Modified Eagle’s Medium (Gibco) 
supplemented with 10% v/v Fetal Bovine Serum (HyClone) and 1% v/v penicillin/streptomycin 
(Gibco). 
 
1.3.2 TKO Library Amplification 
The Toronto human knockout pooled library (TKO) was obtained as a gift from Jason Moffat 
(Addgene #1000000069). For each sub-library (Base 90k library, 91,320 gRNAs; Supplemental 
library 85,180 gRNAs) 1μl of plasmid DNA was added in separate transformations to Endura 
Electrocompetent Cells (Lucigen) and electroporated according to manufacturer’s instructions. 
After 1hr. of incubation in recovery medium (Lucigen), 10μl of culture was removed, serially 
diluted 4x, and plated on ampicillin agar to assess transformation efficiency. The remaining 
transformed cells were added to 100ml LB medium containing 100μg/ml ampicillin and cultured 
overnight at 30°C. Plasmid DNA for each sub-library was then harvested from their respective 
cultures using a Plasmid Plus Maxi Kit (Qiagen) according to the manufacturer’s instructions.  
 
1.3.3 Viral production and quantification 
HEK293T cells were plated at 30-40% confluence in 15cm Biolite culture dishes (Thermo 
Scientific) and incubated for 24hrs prior to transfecting with TKO library plasmid (16μg; 1:1 
Base:Supplemental Libraries), psPAX2 (16μg) and PMDG.2 (16μg) with 144μl Fugene HD 
(Roche) in Opti-MEM (Gibco). The cells were incubated for 24hrs. before aspirating and 
replacing with fresh DMEM culture medium. The medium was then harvested at 48 and 72hrs. 
post-transfection, sterile-filtered, and stored as l mL aliquots. Viral titer was determined by 
plating HAP1 cells at 5000 cells/well on 96-well culture plates containing 10-fold serially diluted 
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TKO viral medium. After 24hrs., the culture medium was replaced with fresh IMDM medium 
containing 1μg/ml puromycin and cultured another 24hrs. Cell viability was then assessed using 
a WST-1 cell proliferation assay (Takara) and the IC50 determined to calculate viral titer. 
 
1.3.4 Generation of Cas9 Expressing Cell Lines 
HEK293T cells were passaged and plated at 30-40% confluence on 6cm Biolite culture dishes( 
Thermo Scientific) and incubated for 24hrs. prior to transfecting with lenticas9-Blast (Addgene 
#52962)  (833ng), psPAX2 (833ng), and PMDG.2 (833ng) with 7.5μl of Fugene HD transfection 
reagent (Roche) according to the manufacturer’s instructions. The cells were incubated for 24hrs. 
before aspirating and replacing the medium and incubating for an additional 24hrs. The medium 
was then harvested at 48 and 72hrs. following transfection and stored at -80°C. Cas9-expressing 
HAP1 cell lines were derived from parent cultures by reverse transduction with Cas9 lentivirus 
and selecting for positive clones by incubation with IMDM medium containing 10μg/ml 
Blastocidin for 72hrs. Expression of Cas9 was then confirmed by western blot of whole-cell 
lysates. 
 
1.3.5 Western Blotting 
Cells were pelleted by centrifugation, resuspended in 1x DPBS (Gibco) and lysed by sonication. 
Total protein content was quantified by Lowry assay (Biorad) and 50μg of total protein diluted to 
final volume of 25μl with DPBS. 1x Lamelli Buffer + SDS was added to the lysates and boiled 
for 15min at 95°C. Lysates were then vortexed, centrifuged, run on 7% SDS tris-acetate gels, and 
transferred at 40mV overnight. Transfer membranes were blocked for 1hr with Odyssey 
Blocking Buffer (Licor) and rocked overnight in OBB + Cas9 (7A9-3A3) Mouse mAb (1:1000) 
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(Cell Signaling Technology). The blots were then washed with 1xTBST and incubated in anti-
mouse stable peroxidase-conjugated goat antibody (Invitrogen) for 1hr. at room temperature. The 
blots were then washed again, treated with SuperSignal West Pico PLUS Chemiluminescent 
substrate (Thermo Scientific) and imaged with an Azure c600 gel imager (Azure Biosystems). 
 
1.3.6 H2O2 Viability Assay 
 
Cells were then plated at 5,000 cells/well with 6x replicates on 96-well culture plates and 
incubated for 24hrs. before treating with 0-200μM H2O2 in DPBS over two consecutive days 
with fresh culture medium being added to all wells prior to each treatment. On the day following 
the final treatment with H2O2 the culture medium from all wells was aspirated, the cells washed 
with DPBS, and 80μL of DPBS added to each well. To these was added 20μL of Resorufin-AM 
(25mM in DPBS) and the cultures incubated for 1hr. before reading the fluorescence of the 
activated dye at 560nm using a Tecan Infinite F500 microplate reader. 
 
1.3.7 TKO CRISPR-Cas9 Essential Gene and Oxidative Stress Screens  
Cas9-expressing HAP1 cultures were expanded and transduced with TKO lentivirus at a MOI of 
≈0.3. After 24hrs incubation, the cell medium was aspirated and replaced with medium 
containing 1μg/ml puromycin and selection allowed to proceed over 72hrs. All selected cells 
were then trypsinized, pooled, and plated at 2.25 x 107 cells (125-fold coverage) in 15cm culture 
dishes (30 control: 30 treatment, total coverage 3,800 per condition) and the pooled population 
was sampled at 4 x 107 as a screen base control and denoted T0. The cultures were incubated 
24hrs to expand to ≈200-fold coverage before treating with 100μM H2O2 solution (treatment) in 
DPBS or DPBS (control) every 24hrs over two days. 72 hrs. after initiating treatment, control 
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and treatment populations were pooled, sampled, replated at 3.75 x 107 cells/plate, and incubated 
a further 24hrs prior to initiating the next cycle of treatment. This process was repeated over four 
additional cycles (denoted T7, T10, T13, T16) with increasing concentrations of H2O2 ramped in 
50μM increments (150, 200, 250, 300μM respectively) with the populations sampled at the 
aforementioned density at the completion of each cycle. Cell counts were performed on the 
pooled population at the end of each cycle to ensure equal coverage between populations. All 
sampled time points were stored at -80°C until the completion of the screen. 
 
1.3.8 Extraction of Genomic DNA 
Cell pellets were thawed and resuspended in 500μl of 1 x TE. To the resuspended cells was then 
added 500μl of 2x lysis buffer (20mM Tris pH 7.5, 10mM EDTA pH 8.0, 100mM NaCl, 1% 
SDS) and 50μl proteinase K solution (Qiagen). The lysates were incubated at 52°C for 1hr. to 
ensure complete lysis. The lysates were then split into equal 500μl volumes and diluted with 
500μl 1x TE before adding 1mL Phenol:Chloroform:Amyl alcohol (50:49:1) (Sigma). The 
emulsions were mixed by inversion for 5min. before centrifuging at 11,000 rpm for 5min. The 
aqueous phase was then transferred to fresh microcentrifuge tubes and an additional 1mL of 
Phenol:Chloroform:Amyl alcohol added. The solutions were mixed by inversion for 5min. 
before centrifuging for 5min. at 11,000rpm. The aqueous layer was then transferred to new 
microcentrifuge tubes to which was then added 100μL of NaOAc (3M; pH 5.2) and two volume 
equivalents of 100% EtOH. The solutions were mixed by inversion and refrigerated at -20°C to 
precipitate the genomic DNA. The solutions were centrifuged at 11,000 rpm for 5min. to pellet 
the DNA. The EtOH was removed, the pellet washed with 500μL of 70% EtOH and centrifuged 
again at 11,000rpm. The EtOH was removed and the pellet allowed to dry for ≈5min. before 
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dissolving in sterile TE buffer. The total recovered gDNA was quantified using a Tecan 
NanoQuant plate and concentrations normalized by agarose in-gel fluorescence. 
 
1.3.9 Illumina Library Preparation and Sequencing 
sgRNAs were recovered from genomic DNA and prepared for Illumina sequencing by nested 
PCR using methods and primers adapted from Moffat et al.  
 
First (outer) PCR: 
Genomic DNA :     3.2μg 
MgCl2 (50mM) :     1μL 
dNTP Mix (10mM):    1μL 
Outer Primer Mix F/R (10μM):   5μL 
Herculase Buffer:    10μL 
Herculase II Fusion Polymerase (Agilent): 0.5μL 
diH2O:      to 50μL 
 
Thermocycler conditions: 
 
1. 98°C 3min. 
2. 98°C 20s. 
3. 52°C 30s. 
4. 72°C 30s.  è repeat steps 2-4 for 22 cycles 
5. 72°C 3min. 
6. 4°C ∞ 
 
16x replicate reactions were conducted for each sample in the screen to ensure sufficient 
coverage. All sample replicates were pooled following completion of the first PCR. 
 
Second (Barcode) PCR: 
 
Pooled outer PCR product:   4μL 
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MgCl2 (50mM) :     1μL 
dNTP Mix (10mM):    1μL 
i5 Barcode Primer F (10μM):   4μL 
i7 Barcode Primer R (10μM):   4μL 
Herculase Buffer:    10μL 
Herculase II Fusion Polymerase (Agilent): 0.5μL 
diH2O:      to 50μL 
 
Thermocycler conditions: 
 
1. 98°C 3min. 
2. 98°C 20s. 
3. 52°C 30s. 
4. 72°C 30s.  è repeat steps 2-4 for 15 cycles 
5. 72°C 3min. 
6. 4°C ∞ 
 
All barcode PCR reactions were conducted in duplicate, pooled upon completion and 
concentrated by spin column purification (Zymo). The concentrated PCR products were resolved 
on 2% agarose gels and ≈200bp barcoded products excised and gel purified using a QIAquick 
gel extraction kit (Qiagen). The prepared Illumina libraries were sequenced using an Illumina 
NextSeq 550 with 150-cycle, paired-end, high-output settings. 
 
1.3.10 Data Analysis 
The raw fastq data was uploaded to the Galaxy server and all subsequent processing conducted 
therein.  In brief, forward and reverse raw fastq files were collapsed into single datasets 
according to their respective sample identities. The read files were then trimmed to remove 5’ 
and 3’ ends of all sequences outside of the 20bp sgRNA sequence. The quality of the reads in 
each file was then assessed using FASTQC to determine if quality filtering was necessary prior 
to downstream processing. All trimmed read files were then filtered with Trimmomatic using the 
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AVGQUAL 20 setting. The processed reads were then aligned to all sgRNAs present in the 
TKO1 Base and Supplemental Libraries using Bowtie2 using the default settings. Read counts 
were then extracted using SAMtools. The raw reads were then piped into the analysis program 
MAGeCK to using default settings to generate ranked lists of candidate genes. 
 
1.4 Results 
HAP1 cultures were transduced with the TKOv1 CRISPR KO library and treated with DPBS 
(control) or increasing concentrations of H2O2 over a period of 16 days. Following completion of 
the screen, populations sampled from each time point were sequenced, normalized by RPM, and 
fold changes calculated from the original population (T0). All sgRNAs exhibiting a fold change 
of at least -2 were filtered out and those targeting core essential genes as determined by Hart et 
al. with a representation of at least three sgRNAs were selected to assess the performance of the 
screen. Average Log2 fold changes were calculated for each essential gene and compared to the 
EGFP, LacZ, and Luciferase non-targeting controls. Although many of these essential genes 
showed decreased average fold changes over the non-targeting controls, few of these reached 
significant values due to the high degree of variability in the performance of individual sgRNAs 
targeted to the same gene. (Figure 7) This inefficiency has been previously noted by others and 
may result from a combination of factors including the nucleotide preference at the first position 
of the PAM, differences in chromatin structure at the target region, and cell line specific 
variability. Such inefficiency complicates the identification of essential genes.  
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Figure 7. Average Log2 Fold changes of all sgRNAs for known essential genes with 
representation of 3 or more at fold changes of less than -2 in HAP1 Control screen population. 
 
To address these issues, several computational tools were developed to confidently distinguish 
between essential genes those that are not essential for cell survival. To enable the identification 
of essential genes for oxidative stress survival we employed MAGeCK, an analysis tool 
developed by Li et al.60 MAGeCK uses an NB distribution to model the variance of individual 
sgRNAs and test their significance. From these individual tests, gene rankings can then be 
generated in accordance to their level of essentiality. MAGeCK was used to identify essential 
genes for all Control and peroxide-treaded time points (T4, T7, T10, T13, T16) relative to the 
starting population (T0). The results were filtered by fold change (less than -1) and p-value (less 
than 0.05) and the top 20 results selected. All control time points included previously identified 
essential genes with the total representation appearing to increase over the course of the screen. 
(Figure 8)  
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Figure 8. Previously identified essential genes identified as hits (shown in red) for each sampled 
time point of the HAP1 control screen. 
 
To ensure that this was the case, the top 50 genes identified for each timepoint of the control 
screen were assessed to determine the proportion of genes deemed essential. From this, it became 
clear that the majority of these genes had not been previously identified as essential genes in 
prior published screens with the proportion of essential genes ranging from 15-25% from one 
timepoint to the next. (Figure 9) 
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Figure 9. Proportion of essential to uncharacterized genes indentified at each timepoint of the 
HAP1 essential gene control screen. 
 
Although the highest number of essential genes were found at the screen endpoint (T16) there 
was no discernable trend suggesting that the number of essential genes identified increased with 
the duration of the screen. That the majority of genes identified by the screen have not been 
found to be essential suggests that the screen lacks sensitivity and that many of these genes may 
be nothing more than false positives. The list of essential genes identified by MAGeCK in the 
H2O2-treated population was compiled and purged of genes previously identified as essential or 
present in the untreated control population and the top 20 remaining hits reported as previously. 
(Table 1) Genes identified in the H2O2 population were aggregated and fed into GORilla61 using 
the aggregated list of control gene hits as a reference background to determine essential 
biological processes involved in oxidative stress. From this, only a minimal enrichment for 
cellular aromatic compound metabolic processes (GO:0006725) was identified with no 
enrichment for either function or component. Although individual hits here identified may 
indeed be essential for survival under conditions of oxidative stress, these ontology results 
indicate that many of these identified hits may not be involved in the cellular response to 
oxidative stress and represent false positives.  
Control T13 Control T16
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Essential 
Nonessential
Uncharacterized
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Control H2O2-Treated 
T4 T7 T10 T13 T16 T4 T7 T10 T13 T16 
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Table 1. Top 20 essential genes for Control and H2O2-treated screen populations exhibiting Log2 
fold changes greater than -1 over all sampled time points (T4, T7, T10, T13, T16). 
 
1.5 Discussion 
Herein, we attempted to systematically identify the essential genes of the cellular oxidative stress 
response using whole-genome CRISPR knockout libraries. Cas9-expressing human haploid 
HAP1 cultures were treated with a ramped concentration of H2O2 starting just below the 
experimentally determined62 IC50 from 100-300µM and the population sampled at regular 
intervals alongside a control population to assess the proper functioning of the screen. The top 20 
hits from each time point in the untreated control population revealed an increasing 
representation of core essential genes as previously identified by Hart et al.33 indicative of proper 
screen function. The top prospective gene hits for the H2O2-treated population were determined 
after removing all high scoring candidates that were represented in either previously identified 
core essential genes or control screens. The aggregate list of these genes corresponded very little 
in their known functions or the processes in which they participate. This was unfortunate as our 
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original intention had been to broadly identify key components of the oxidative stress response. 
That we were unable to accomplish this may be due to the lack of sensitivity suggested by the 
prevalence of genes in the control screen that have not been shown to be essential. This might 
have resulted from a lack of statistical power, an issue that could be easily corrected by the 
inclusion of biological replicates for the screen. It may also be due to the inherent limitations of 
using hydrogen peroxide as genotoxic stressor. The size of the TKOv1 library necessitated that 
multiple large-scale cultures be maintained simultaneously. This placed limitations on how H2O2 
could be introduced to the screen population. As it was technically infeasible to maintain a 
constant level of H2O2 over the course of the screen for lack of straightforward methods to 
constantly generate H2O2 or monitor it, simple bolus doses of peroxide at the indicated 
concentrations were introduced to fresh culture medium every 24hrs. This might have resulted in 
high localized concentrations of H2O2 that indiscriminately induced cell death irrespective of 
genetic vulnerabilities. The short duration of the stressor may also have contributed to the lack of 
representation of genes known to play a part in mediating oxidative stress survival. Given all of 
these limitations it is possible that only those genes whose loss induces the strongest sensitivity 
to oxidative insult could have been identified using this screen approach. Indeed, there are 
several top scoring genes that are known to play a role in cell survival. These include 
antiapoptotic factors BCL2 and 3. (Figure 10)  
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Figure 10. Identified essential genes candidates implicated in cell survival. 
 
Other genes identified here as hits were directly implicated or indirectly associated with 
processes critical to cellular survival under stress conditions including cell growth (IGF2BP1, 
YPEL3, GPR137, SMPD4) (Figure 11), mitochondrial maintenance (SLC25A33, DNAJC19, 
NDUFAF1, COX7A1) (Figure 12), lipid biogenesis (PRKAG1, PTPLAD2) (Figure 13), DNA 
repair (HNRNPA3, RBM45, RAG2, PPP4R2) (Figure 14), and oxidative stress (BASP1, 
MMACHC, NDUFB7, PPOX, PON3, HIGD1A, VHLL). (Figure 15)  
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Figure 11. Identified essential gene candidates implicated in cell growth and proliferation. 
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Figure 12. Identified essential gene candidates implicated in mitochondrial maintenance.  
 
Figure 13. Identified essential gene candidates implicated in lipid biogenesis.  
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Figure 14. Identified essential gene candidates implicated in DNA damage response and repair.  
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Figure 15. Identified essential gene candidates implicated in the cellular oxidative stress 
response.  
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Of particular interest here are MMACHC and VHLL, two genes with distinctly different 
functions that have been implicated in oxidative stress but whose function is completely 
unknown. Metabolism of Cobalamin C (MMACHC) has been proposed by homology to play a 
role in the intracellular processing and trafficking of cobalamin. Vitamin B12 deficiency has been 
associated with increased oxidative stress and has been proposed to mitigate oxidative stress by 
scavenging ROS or maintaining homocysteine metabolism.63 Whether or not vitamin B12 and, by 
association, MMACHC function in either of these capacities is, as of now, unknown. For DNA 
repair, RBM45 has been implicated as an important regulator of the DNA damage response64 
whereas HNRNPA3 has been implicated in telomere stability among other functions.65,66,67 Both 
of these proteins though have been implicated in onset of ALS and so might represent interesting 
candidates for further study. Finally, DNAJC19 is a chaperone protein associated with 
mitochondrial maintenance and repair that is frequently mutated in a number of diseases linked 
to oxidative stress including cardiac dysfunction and Parkinson’s disease.68 There are also a 
number of genes represented as top hits that, as of yet, have no known function. These include 
uncharacterized GPCRs (OR2A25, OR4C16, OR5AP2, OR6C1), zinc-finger proteins (ZNF583, 
ZFP69B), and ORFs (C5orf52, C17orf67, C11orf71, C6orf201). (Figure 16) It would be of 
interest to see if these in fact do play a role in the survival of the cell under conditions of 
oxidative stress. In all these cases, individual validation of the genes would need be conducted to 
confirm the screen results before further work could be proposed to characterize their functions.  
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Figure 16. Identified essential gene candidates with uncharacterized functions. 
 
A recent and more comprehensive study published by Dubreuil et al.69 however, tempers our 
expectations on the validity of these results. Here, CRISPR KO screens were used in 
combination with shRNA screens to identify mediators of oxidative stress. Identified hits were 
then validated with a second round of screens using CRISPR KO and CRISPRi sublibraries 
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followed by single hit growth assays. Similar to what was observed in our own screens, the 
identified genes included both known and unexpected mediators of oxidative stress. From their 
screens, they found that PRDX1, a peroxiredoxin, sensitized cells to oxidative stress whereas 
KEAP1, a negative regulator of the master transcription factor for oxidative stress, was 
protective. This was also observed in our screens at the final timepoint under the highest levels 
of oxidative stress (T16). However, our screens failed to identify any of the other major 
antioxidative genes identified including the antioxidative protein Catalase (CAT), the iron 
homeostasis regulator IREB2, members of the peroxisomal import pathway (PEX), and the 
pentose phosphate pathway mediator PGD. That some of the genes identified in these screens 
were also found in our own but so many others missed supports our supposition that the cells in 
culture were not sufficiently stress with H2O2 to promote genetic selection. In their screens, 
Dubreuil et al.69 used multiple treatments at the experimentally determined IC50 of their cell 
models, allowing the cultures to recover for several days before starting another round of 
treatment. This suggests that our single treatment was not of sufficient duration to induce 
genotoxic stress and that many of the genes identified are likely spurious. This issue would 
necessitate that another screen be performed using multiple treatments of a fixed rather than a 
ramped H2O2 concentration. Dubreuil et al.69 along with many others 38,70,71 have demonstrated 
the usefulness of performing identical screens with different methods in order to more reliably 
identify essential genes for the process in question. Given this, it may be prudent to combine 
whole genome CRISPR KO screens with CRISPR activation screens (CRISPRa) to identify 
previously unknown mediators of the oxidative stress response. This would provide further 
experimental support for the published results of Dubreuil et al.69 and may, with the addition of 
CRISPRa, lead to the identification of further genes that have not yet been uncovered.   
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1.6 Conclusions 
Reactive oxygen species play critical roles in cellular function both normal and abnormal. As 
such, numerous proteins that deal with their regulation are encoded in the genome, many with 
roles that have yet to be defined. We have attempted to employ the recently developed CRISPR-
Cas9 knockout screen libraries to identify these unknown regulators. While a preliminary screen 
on a control population successfully identified some previously uncovered essential genes a lack 
of sensitivity was observed and performing the screen on a population treated with H2O2 likewise 
yielded sparse and largely unexpected putative gene hits. A recently published study employing 
nearly identical methods to our own supported very few of these and identified many more that 
were entirely absent from our screens. This undermines whatever confidence we might have in 
the genes here identified playing any part in regulating cellular ROS. It also suggests that this 
failure could be corrected with a simple modification to how selective pressure was applied to 
the screen cultures along with the inclusion of screen replicates. Making these corrections and 
employing a CRISPRa whole genome screen to complement the CRISPR KO screen would 
amend the faults of our previous effort, lend support to the comprehensive work of Dubreuil et 
al.69, and provide an opportunity to uncover further genes involved in the cell’s response to 
oxidative stress.  
 
 
 
 
 
 
 37 
 
 
Chapter 3 
 
Uncovering Functional Redundancy in DHHC-family Palmitoyltransferases 
using CRISPR-Cpf1 Duplex Genomic Screens 
 
3.1 Introduction 
3.1.1 Protein Lipidation in Cell Biology 
The post-translational modification of newly synthesized proteins is a characteristic feature of 
eukaryotic cell biology. Many examples of these modifications have been catalogued ranging 
from the addition of small molecules that occurs in phosphorylation, acetylation, methylation, 
and N-glycosylation to whole proteins as in ubiquitinylation and SUMOylation.72 Many of these 
modifications are functionally reversible, with the addition and removal of each modification 
conducted by distinct groups of ‘writer’ and ‘eraser’ proteins respectively.73The presence or 
absence of these modifications play critical roles in protein function by permitting tight control 
over subcellular localization, protein-protein interactions, and enzymatic activity.74 Lipidation, 
the post-translational modification of proteins with acyl fatty acids, accomplishes this by 
promoting association with the cellular and subcellular membranes and includes both reversible 
and irreversible modifications.72 Of all of the observed lipid modifications so far only 
palmitoylation, the S-acylation of cysteine residues with palmitate, has been shown to be 
reversible.73 The addition of palmitate is carried out by a large family of membrane-associated 
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DHHC protein acyl transferases (PATs) and removal by less well understood protein 
thioesterases such as acylprotein thioesterase 1 (APT1) and 2 (APT2) and the ABDH17 
proteins.74 Cycling between palmitoylated and depalmitoylated states catalyzed by PATs and 
thioesterases respectively permit close control of protein subcellular localization and, as a 
consequence, protein function.75 (Figure 17) The importance of these palmitoylation cycles to 
normal cellular function is highlighted by the consequences of their dysfunction which has been 
associated with a wide assortment of pathologies including schizophrenia, developmental 
defects, and cancer.76 
 
 
 
 
 
 
 
 
Figure 17. The varied roles of DHHC-family palmitoyltransferases. Palmitoylation of protein 
substrates by DHHC PATs promotes association of the target with the membrane and promotes 
movement through the secretory pathway. Palmitoylation my also promote stability of the target 
protein or specific protein-protein interactions.   
 
3.1.2 The DHHC Family Acyltransferases 
The reversible addition of palmitate to protein cysteine residues is carried out by a large family 
of DHHC PATs, so named for the conserved Aspartate-Histidine-Histidine-Cysteine catalytic 
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motif found in all of its members.77 First identified in yeast, DHHC PATs have been found 
across multiple plant and animal species with a total of 23 distinct genes found in mice and 
humans respectively.78All DHHC PATs are membrane associated and share a conserved core of 
4-6 transmembrane domains with a cysteine-rich domain containing the catalytic DHHC motif 
on an cytosolic loop.79 Beyond this core structure however, DHHC PATs exhibit only limited 
sequence homology.80 DHHCs catalyzed the transfer of palmitate to their associated substrates 
by two-step ping-pong mechanism.81 The first step involves the formation of an acyl-
intermediate between the palmitoyltransferase and palmitoyl-CoA through autopalmitoylation 
followed by the transfer of palmitoyl group to the substrate in the second step.82The cysteine of 
the DHHC catalytic motif is essential for both autopalmitoylation and transfer of the palmitoyl 
group whereas loss of the first histidine only prevents the latter.83  
 
3.1.3 Inter- and Intracellular Distribution of DHHC-Family Acyltransferases 
DHHCs PATs have been found in association with the membranes of many subcellular 
compartments including the Endoplasmic Reticulum (ER), Golgi apparatus (GA), plasma 
membrane (PM), and transport vesicles. The work of Ohno et al.84 was the first comprehensive 
effort to determine the subcellular distribution of DHHC PATs. From this it was discovered that 
DHHCs 1,6,11,13,14 and 19 were found to stably associate with the ER, DHHCs 3,4,7,8,15,17, 
and 18 with the GA, and DHHCs 5, 20, and 21 with the PM. DHHCs 2, 9, 12, and 22 by contrast 
were found in both the ER and GA. Subsequent studies have revealed alternate localization 
patterns for some of these DHHCs and may be reflective of differences in cell type.85 DHHC 1 
was found to localize to Rab5+ early endosomes86 in neurons, and both the GA and ER in HeLa 
cells.87 Localization of DHHC2 to both the ER and GA was reported as previously88,89 along 
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with evidence of localization to the PM90,91,92 and endosomes.92 DHHC4 was found to localized 
to the ER93 in addition to the GA.94,95 DHHC 11, like the closely related DHHC1, was also found 
to localize to endosomes.96 DHHC13 was found to localized predominately to the GA96,97,98 but 
also endosomal vesicles.97,98DHHC14, like the related DHHC9, has been found to localize to the 
GA.99The localization of DHHC16, previously undetermined, was established at the ER.88,100 
Subsequent work on DHHC19 revealed localization at the GA.101 Similar to DHHC2, DHHC20 
showed dispersed localization in multiple subcellular compartments.102 DHHC21 was found to 
alternately localize to the GA.103 Absent from previous work, DHHC23 was subsequently shown 
to localize to the GA and trans-Golgi network.104 With some exceptions, the majority of DHHCs 
stably partition between the ER, GA, and PM, the major subcellular organelles involved in the 
classic secretory pathway. Movement of substrate proteins through the secretory pathway is 
determined by the competing actions of PATs and thioesterases, with palmitoylation by the 
resident PATs in each subcellular organelle promoting membrane association and driving them 
forward through the secretory pathway. Given this, it may be presumed that every substrate has a 
specific PATs or set of PATs within each organelle with which it selectively associates for 
palmitoylation. With a larger number of PATs residing in the GA than the ER and PM 
respectively, this would indicate that PATs localized to the former are responsible palmitoylating 
a narrower range of substrates than the latter; that GA resident PATs exhibit inherently greater 
substrate selectivity whereas those of ER and PM are more promiscuous. The specific features of 
each PAT that determine its subcellular localization are still largely unknown. There is high 
degree of conservation within the structural core, containing the transmembrane and the 
cysteine-rich catalytic domains of all DHHCs. This would indicate that the structural 
determinates of subcellular localization and, possibly, substrate preference reside within the N- 
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and C-terminal regions where nearly all variability between DHHCs is found. In support of this, 
Greaves et al. found that the C-terminal domain of DHHC2 was found to be necessary for its 
localization to the PM.92 ER-resident DHHCs 4 and 6 were found to contain C-terminal lysine-
based sorting signals that were essential for their retention and, indeed, were sufficient to alter 
the localization of non-ER resident PATs to this organelle.93 Aside from these examples, no 
subsequent work has been done to investigate the variable N- and C-terminal domains of other 
DHHCs and how they influence their subcellular localization. Surprisingly, a systematic 
investigation of these questions has not been undertaken and should be done to resolve them. 
 
3.1.4 Substrate Preference and Functional Redundancy within DHHC-Family 
Acyltransferases 
Of the questions surrounding the function of palmitoyl transferases, none is more intriguing than 
that of substrate preference. At the heart of this question is an apparent paradox. All of the model 
organisms surveyed have been found to contain multiple, distinct PATs encoded within their 
genome, with a greatest number being found in higher organisms, humans and mice with 23 
respectively. This would seem to imply a high degree of substrate specificity, each PAT having a 
defined set of proteins that it palmitoylates to exclusion of others. This would be in keeping with 
the large number of DHHCs found in many organisms; if DHHCs PATs did not have some 
degree of inherent substrate specificity there would no selective advantage to retaining them and 
other evolutionary time their numbers would be whittled down to an essential few, maybe a 
single PAT for each organelle of the secretory pathway. This rationale was driving force behind 
initial efforts to identify the unique substrates of each PAT and the principles that dictate their 
specificity. An understanding of these could, in principle, guide the development of 
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pharmacological compounds targeted to specific DHHCs involved in particular disease-causing 
pathways, while leaving the rest to function unperturbed. Indeed 2-bromopalmitate, the only 
PAT-specific inhibitor then developed, targeted the catalytic domain and therefore operated 
indiscriminately across all PATs to impede palmitoylation.105 The work of Ohno et al.106 and 
subsequent efforts however yielded results contrary to this expectation. Screening of DHHCs 
PATs against substrates of interest by H3-palmitate labeling reveled a propensity of certain 
DHHCs to palmitoylate these substrates over others. Knockdown or knockout of these same 
PATs however, did not abolish palmitoylation of these same substrates in vitro or greatly impede 
their regular function. This was likewise demonstrated by Roth et al. where single knockouts of 
yeast DHHCs failed to alter the palmitoylation state of multiple palmitoylated proteins, an 
outcome that only occurred when five or more DHHCs were simultaneously inactivated.107 This 
would imply an unexpected degree of functional redundancy between PATs. The extent of this 
functional redundancy and the reasons for it remain unresolved.108 DHHCs are often grouped 
into subfamilies on the basis of sequence similarity. (Figure 18) Presumably, DHHCs within 
these subfamilies possess similar structures, particularly at the N- and C-terminal domains 
believed to be responsible for intracellular localization and/or substrate recognition. This would 
result in the palmitoylation of a similar panel of substrates either by either driving localization to 
specific subcellular compartments or association with specific features of the substrate. The 
members of certain DHHC subfamilies are known to have relatively complex structural features 
outside of the cysteine-rich catalytic domain. DHHCs 13 and 17 are known to have ankyrin-
repeat binding domains while DHHCs 5, and 8 possess PDZ-binding motifs and DHHC6 an 
SH3-binding motif.109 These have all been shown to promote association with and palmitoylation 
of particular substrates. Other DHHCs such as Golgi resident DHHC3 and 7 however seem to 
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lack such structural features and do not seem to exhibit much discrimination between the 
substrates that they palmitoylate. This would suggest that DHHC PATs may be subdivided into 
two groups 1) those that exhibit lower activity to all possible substrates but a high degree of 
selectivity toward a few and, 2) those that have high activity toward all substrates but exhibit 
little to no selectivity between them. Localization may also play an important role in substrate 
specificity as DHHCs can only palmitoylate substrates that occupy the same subcellular space. 
DHHCs within the same cellular organelles may then be expected to palmitoylate the same 
substrates by simple proximity. This would result in a high degree of functional redundancy 
between GA-resident PATs and a lesser degree in those of the ER and PM. It is probable that 
both of these considerations play a role in determining the substrate panel of any given DHHC 
such that all DHHCs within a given organelle may palmitoylate any substrate within their 
immediate vicinity but will associate more with those that possess complementary structural 
motifs. Therefore, the loss of any given DHHC may be compensated to some degree by the 
others that occupy the same space within the cell and mask any resulting phenotype. The 
expression of DHHCs varies from one tissue to another92 and so the effects of losing certain 
DHHCs may be more pronounced than others, particularly if they possess substrate recognition 
domains. It can be predicted then that some degree of functional redundancy may exist between 
PATs localized to the same organelle and even more so if they derive from the same structural 
subclass.  
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Figure 18. Sequence homology relationships between DHHC-family palmitoyltransferases. The 
high degree of relatedness between DHHCs 2/20, 3/7, 5/8, and 18/19 denote distinct subfamilies 
with presumed similarity in function and substrate preference.  
 
3.1.5 Ras GTPases in Normal and Aberrant Cellular Processes 
The Ras proteins make up a superfamily of over 150 small, monomeric GTPases that are well 
conserved in eukaryotes.110 Members of the Ras-family GTPases function as nodes in signaling 
pathways, interacting with multiple downstream effectors upon activation by external stimuli, 
that, in turn, regulate signaling networks that control the expression of genes involved in cell 
proliferation, differentiation and survival.111 The Ras GTPases are therefore essential drivers of 
normal cellular proliferation. Given their critical role in this process however, it is unsurprising 
they are all to often the culprits in the rampant cell growth that is characteristic of aggressive 
malignancies.112 Ras activation is triggered by the exchange of bound GDP for GTP, promoting a 
conformational change that increases the affinity of Ras for its downstream effectors.113 This 
state of activation persists until the bound GTP is hydrolyzed to GDP. Ras, by itself, is 
intrinsically poor at carrying out either of these actions and so relies on associated Guanine-
nucleotide-exchange factors (GEFs) and GTPase-activating proteins (GAPs) to carry promote 
activation and inactivation respectively.114 Aberrant function of Ras or any of its associated 
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GEFs and GAPs can result in inappropriate activation of Ras and its downstream effectors. 
Specific mutations in Ras that promoted a constitutively active state by preventing GTP 
exchange were responsible for the initial discovery of Ras and recognition of its role in cancer 
progression.115 All of the primary Ras isoforms require membrane localization in order to access 
their downstream targets and drive proliferative signaling.116 This assertion is supported by the 
extensive lipid post-translational modifications that have been found in association with Ras. 
Canonical Ras isoforms all contain C-terminal cysteine motifs that serve as the recognition 
signal and attachment point for C15 or C20 lipids by farnesyl or geranylgeranyl transferases 
respectively.117 This modification permits some degree of membrane interaction but has been 
found to be insufficient for the stable membrane association required for trafficking to the 
plasma membrane.118 This association with the membrane and ultimately the function of Ras is 
controlled by antagonistic cycles of palmitoylation/depalmtoylation119 and this dependence 
suggests that DHHC acyltransferases may play an essential role in Ras-dependent proliferation. 
Ras isoforms NRas and HRas have already been shown to be substrates for DHHC9, undergoing 
palmitoylation at the Golgi before trafficking to the plasma membrane.120 Furthermore, Ras 
isoforms are unable to drive cellular proliferation when made palmitoylation-deficient either by 
genetic mutation or by chemical inhibition of DHHC palmitoyltransferases.121,122 This indicates 
that there are likely many other Ras isoforms and associated proteins that are substrates for 
acyltransferases.123  
 
3.2 Research Justification and Objectives 
The question of functional redundancy between DHHC PATs remains unresolved. To address 
this, we aim to employ a pooled genetic screen approach targeting all known DHHC genes. It has 
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been previously shown that single knockout or knockdown of individual DHHCs results in a null 
phenotype due to compensation by the remaining unaffected DHHCs. In order to get around this 
issue we use the CRISPR-Cpf1 system paired with randomized duplex crRNA arrays targeted to 
all known DHHCs. (Scheme 2) Should any synergy or functional redundancy exist between a 
pair of DHHCs duplex arrays containing only a single targeting sequence for either PAT should 
yield a much less noticeable effect than an array containing crRNAs targeted to both. Libraries 
were constructed for both human and mouse genetic models following the methods developed by 
Chow et al.124 Screens were then performed using these libraries in a general human haploid cell 
model and a more strictly controlled Ras-dependent mouse cell model. The human HAP1 cells 
are a nearly haploid cell line and so should prove more sensitive to genetic knockout. They will 
be used to validate the screen methodology prior to conducting screens in Ras-dependent cell 
models.  The mouse MEF cell lines, meanwhile, have been engineered so as to be dependent of a 
single Ras isoform for their survival. As such, any disruption in the signaling pathway of that 
specific Ras isoform will cause an arrest in the cell’s growth. Since Ras and many of its affiliates 
require palmitoylation to properly function, the loss of any PATs responsible for carrying this 
out will be lethal to any cell that has been made deficient in them. These Rasless MEFs also 
provide us with a unique opportunity to identify other PATs involved in Ras-dependent growth 
beyond Ras itself, something that has not yet been attempted. These screens should provide a 
good basis with which to investigate these fundamental questions surrounding the function of 
palmitoyltransferases.   
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Scheme 2. Methods to be used for Cpf1 library synthesis and subsequent pooled KO screen. 
 
3.3 Methodology 
3.3.1 Cell Culture 
Isogenic Ras-dependent MEF cell lines (HRas, NRas, KRas4a and KRas4b) were obtained from 
the National Cancer Institute (NCI) and cultured in Dulbecco’s Modified Eagle’s Medium 
(Gibco) supplemented with 10% v/v Fetal Bovine Serum (HyClone) and 1% v/v 
penicillin/streptomycin (Gibco). All cell lines were maintained under selection (Puromycin 
2.5μg/mL or Blastocidin, 4μg/mL) to ensure continued Ras-dependency. HAP1 cells were 
obtained from the laboratory of G. Van der Goot (Ecole Polytechnique Fédérale de Lausanne) 
and cultured in Iscove’s Modified Dulbecco’s Medium (Gibco) supplemented with 10% v/v 
Fetal Bovine Serum (HyClone) and 1% v/v penicillin/streptomycin (Gibco). HEK293T cell lines 
were maintained Dulbecco’s Modified Eagle’s Medium (Gibco) supplemented with 10% v/v 
Fetal Bovine Serum (HyClone) and 1% v/v penicillin/streptomycin (Gibco). 
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3.3.2 Design and Synthesis of mDHHC Arrays 
 
AsCpf1/LbCpf1 sgRNAs using the TTTN protospacer adjacent motif (PAM) were identified 
within the coding sequence of all major zDHHC genes contained within the mouse genome using 
the CRISPR design tools provided by Benchling. All possible sgRNAs for each gene were 
compiled and four sgRNAs selected per gene with preference given to those located 5’ to the 
conserved cysteine-rich catalytic domain and/or exhibiting a high off-target score (i.e those that 
exhibit low probability of cutting elsewhere in the genome) for a total of 96 DHHC-targeted 
sgRNAs. To this list of targeting sgRNAs was added 52 non-targeting control sgRNAs derived 
from those used by Chow et al.124 Common 5’ and 3’ homology arms along with spacers 
containing the Cpf1 direct repeat were appended to all sgRNAs within the list and randomized to 
generate all possible combinations of targeting and control sgRNAs. Duplicate sequences 
(sgRNA 1 + sgRNA 1) and mirror duplicates (where sgRNA 1 + sgRNA2 = sgRNA2 + sgRNA 
1) were removed to give a list of 10,878 unique duplex arrays. To these DHHC-specific arrarys 
was added 91 arrays targeting the primary Ras isoforms (NRas, HRas, KRas4a, and KRas4b) 
bringing the final library to 10,969 unique duplex arrarys. These were submitted to CustomArray 
Inc. for synthesis. 
3.3.3 Design and Synthesis of hDHHC Arrays 
AsCpf1/LbCpf1 sgRNAs using the TTTN protospacer adjacent motif (PAM) were identified 
within the coding sequence of all major zDHHC genes contained within the human genome 
using the CRISPR design tools provided by Benchling. All possible sgRNAs for each gene were 
compiled and four sgRNAs selected per gene with preference given to those located 5’ to the 
conserved cysteine-rich catalytic domain and/or exhibiting a high off-target score (i.e those that 
exhibit low probability of cutting elsewhere in the genome) for a total of 92 DHHC-targeted 
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sgRNAs. To this list of DHHC-targeted sgRNAs was added 52 randomly generated non-
targeting control sgRNAs. Random 20-bp oligonucleotide sequences were generated using 
RSAT and the resulting output purged of any redundant sequences using the Sort and Unique 
lines tools from Galaxy. The output was subsequently uploaded to Cas-OFFinder125 and all 
sequences exhibiting fewer than 4bp mismatches to regions of Homo sapiens hg38 reference 
genome removed. The 52 non-targeting control sequences were then selected randomly from this 
filtered list. Additionally, crRNAs against genes selected from the review of essential genes 
produced by Telenti et al.126 (hEIF3B, hDICER1, hPOLR2A, hNRF1; 3 sgRNAs per gene) were 
also included as controls to evaluate screen function. Common 5’ and 3’ homology arms along 
with spacers containing the Cpf1 direct repeat were appended to all sgRNAs within the list and 
randomized to generate all possible combinations of targeting and control sgRNAs. Duplicate 
sequences (sgRNA 1 + sgRNA 1) and mirror duplicates (where sgRNA 1 + sgRNA2 = sgRNA2 
+ sgRNA 1) were removed to give a list of 12090 unique duplex arrays. These were submitted to 
CustomArray Inc. for synthesis. 
 
3.3.4 Cloning of mDHHC/hDHHC sgRNA Libraries 
The parent lentiviral vectors pRC49 (puromycin resistance, firefly luciferase, nuclear EGFP) and 
pRC11 (puromycin resistance) for cloning of the mDHHC and hDHHC libraries respectively 
were obtained as a gift from Sidi Chen (Addgene # 123363) and digested with Esp3I according 
to the following conditions: 
-5μg Plasmid DNA 
-3μL FastDigest Esp3I (ThermoFisher #FD0454) 
-4μL FastAP (ThermoFisher #EF0651) 
-5μL 10x FastDigest Buffer  
-ddH2O to 50μL 
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Thermocycler conditions: 37°C for 60 minutes. 
The plasmid digestion was run on a 1% agarose gel with an uncut control to confirm 
linearization and the digested plasmid extracted using a QIAquick Gel Extraction Kit (Qiagen). 
The synthesized hDHHC pooled oligo array was amplified by PCR to append homology arms 
using the following primers and conditions: 
DHHCarray_F : 
TAACTTGAAAGTATTTCGATTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAAC                
ACCG  
DHHCarray_R: 
TTGTCTCAAGATCTAGTTGATATCGGATCCACGCCAAGCTT 
 
-1μL mDHHC oligo array  
-2.5μL DHHCarray_F (10μM) 
-2.5μL DHHCarray_R (10μM) 
-25μL Phusion Flash High-Fidelity PCR Master Mix (ThermoFisher #F548S) 
-19μL ddH2O 
 
Thermocycler conditions: 
1. 98°C 1min. 
2. 98°C 1s. 
3. 59°C 5s. 
4. 72°C 10s.  è repeat steps 2-4 for 32 cycles 
5. 72°C 2min. 
6. 4°C ∞ 
 
The PCR product was confirmed by running the reaction on a 1% agarose gel (≈210 bp 
amplicon) and extracted with a QIAquick Gel Extraction Kit. 
 
The PCR products were then cloned into linearized pRC11 by Gibson assembly according to the 
following procedure: 
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-330ng Esp3I-digested pRC11  
-50ng PCR-amplified mDHHC library 
-10μL 2x Gibson Assembly Master Mix (New England Biolabs #E2611S) 
-ddH2O to 20μL 
 
Thermocycler conditions: 50°C for 60 minutes. 
3.3.5 Cpf1 Library Amplification 
Of the Gibson reaction product, 2μl was added in separate transformations to Endura 
Electrocompetent Cells (Lucigen) and electroporated according to manufacturers instructions. 
After 1hr. of incubation in recovery medium (Lucigen), 10μl of culture was removed, diluted 
1:100 and 1:10000, and plated on ampicillin agar to assess transformation efficiency. The 
remaining transformed cells were streaked on 15cm LB agar plates containing 100μg/ml 
ampicillin (2x per transformation) and cultured overnight at 37°C. Plasmid DNA was then 
harvested using a EndoFree Plasmid Maxi Kit (Qiagen) according to the manufacturers 
instructions. Successful cloning of the sgRNA arrays into the parent vector was confirmed by 
NotI/XhoI digest against the parent vector. 
 
3.3.6 Viral production and quantification 
HEK293T cells were plated at 60-80% confluence in 15cm Biolite culture dishes (Thermo 
Scientific) and incubated for 24hrs prior to transfecting with pRC49_mDHHC or 
pRC11_hDHHC library plasmid (8μg), psPAX2 (4.8μg) and PMDG.2 (3.2μg) with 
Lipofectamine 3000 (Thermo) transfection reagent in Opti-MEM following the manufactures 
instructions . The cells were incubated for 6hrs. before aspirating and replacing with fresh 
DMEM culture medium. The medium was then harvested at 24 and 48hrs. post-transfection, 
sterile-filtered, and stored as l mL aliquots. Viral titer was determined by plating HAP1 cells at 
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10000 cells/well on 96-well culture plates containing 10-fold serially-diluted TKO viral medium. 
After 24hrs., the culture medium was replaced with fresh IMDM medium containing 1μg/ml 
puromycin and cultured another 24hrs. Cell viability was then assessed using WST-1 cell 
proliferation assay (Roche) and measured cell viability used to determine viral titer. 
 
3.3.7 Generation of Cpf1-Expressing Cell Lines 
HEK293T cells were passaged and plated at 30-40% confluence on 6cm Biolite culture dishes 
and incubated for 24hrs. prior to transfecting with pCLHCX-AsCpf1 (1250ng) and pCL-Ampho 
(1250ng) with 7.5μl of Fugene HD transfection reagent according to the manufacturer’s 
instructions. The cells were incubated for 24hrs. before aspirating and replacing the medium and 
incubating for an additional 24hrs. The medium was then harvested at 48 and 72hrs. following 
transfection and stored at -80°C. Cpf1-expressing HAP1 cell lines were derived from parent 
cultures by reverse transduction with AsCpf1 retrovirus and selecting for positive clones by 
incubation with DMEM medium containing 200μg/ml Hygromycin for 72hrs.  
 
3.3.8 Western Blotting 
Cells were pelleted by centrifugation, resuspended in 1x DPBS and lysed by sonication. Total 
protein content was quantified by Lowry assay and 25μg of total protein diluted to final volume 
of 20μl with DPBS. 1x Lamelli Buffer + SDS was added to the lysates and boiled for 15min at 
95°C. Lysates were then vortexed, centrifuged, run on 7% SDS tris-acetate gels, and transferred 
at 40mV for 12hrs. Transfer membranes were blocked for 1hr with Odyssey Blocking Buffer 
(Licor) and rocked overnight in OBB + 6x-His Tag Mouse mAb (1:1000) (Invitrogen). The blots 
were then washed with 1xTBST and incubated in anti-mouse stable peroxidase-conjugated goat 
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antibody (Invitrogen) for 1hr. at room temperature. The blots were then washed again, treated 
with SuperSignalTM West Femto Chemiluminescent substrate (Thermo Scientific) and imaged 
with an Azure c600 gel imager (Azure Biosystems). 
 
3.3.9 hDHHC CRISPR-Cpf1 Duplex Knockout Screen 
 
Cpf1-expressing HAP1 cultures were expanded and transduced with pRC11_hDHHC lentivirus 
at 300-fold library coverage and an MOI of ≈0.2. After 24hrs incubation, the cell medium was 
aspirated and replaced with medium containing 1μg/ml puromycin and selection allowed to 
proceed over 48hrs or until cells reached confluence. All selected cells were then collected and 
subdivided over 3x replicate 15cm culture dishes at 300-fold coverage and a 300-fold sample 
retained for each replicate as a screen base control and denoted T0. The cultures were maintained 
for 3 weeks under puromycin and hygromycin selection, passaging every 3-4 days to prevent the 
cultures from reaching confluence and maintaining them at respective initial library coverage. 
After 18 days (approximately 5 passages), the cultures were collected and sampled at 300-fold  
coverage(T18). The T0 and T18 time point replicates for each sample were stored at -80°C. 
 
3.3.10 Extraction of Genomic DNA 
Cell pellets were thawed and resuspended in 200μl of 1 x DPBS. The genomic DNA was then 
extracted using DNeasy Blood and Tissue Kit (Qiagen) following the manufacturer’s 
instructions. The total recovered gDNA was quantified using a Tecan NanoQuant plate. 
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3.3.11 Illumina Library Preparation and Sequencing 
crRNAs were recovered from genomic DNA and prepared for Illumina sequencing by nested 
PCR using methods and primers adapted from Chen et al.  
 
First (outer) PCR: 
Genomic DNA :     3μg 
MgCl2 (50mM) :     1μL 
dNTP Mix (10mM):    1μL 
DHHC_vrd1_F (10μM)   2.5μL  
DHHC_vrd1_R (10μM)   2.5μL 
Herculase Buffer:    10μL 
Herculase II Fusion Polymerase (Agilent): 0.5μL 
diH2O:      to 50μL 
 
Thermocycler conditions: 
 
1. 98°C 3min. 
2. 98°C 20s. 
3. 52°C 30s. 
4. 72°C 30s.  è repeat steps 2-4 for 22 cycles 
5. 72°C 3min. 
6. 4°C ∞ 
 
5x replicate reactions were conducted for each sample in the screen to ensure sufficient 
coverage. All sample replicates were pooled following completion of the first PCR. 
 
Second (Barcode) PCR: 
Pooled outer PCR product:   4μL 
MgCl2 (50mM) :     1μL 
dNTP Mix (10mM):    1μL 
DHHC Index Adaptor F (10μM)  2.5μL  
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DHHC Index Adaptor R (10μM)  2.5μL 
Herculase Buffer:    10μL 
Herculase II Fusion Polymerase (Agilent): 0.5μL 
diH2O:      to 50μL 
 
 
Thermocycler conditions: 
1. 98°C 3min. 
2. 98°C 20s. 
3. 52°C 30s. 
4. 72°C 30s.  è repeat steps 2-4 for 16 cycles 
5. 72°C 3min. 
6. 4°C ∞ 
 
All barcode PCR reactions were conducted in duplicate, pooled upon completion and 
concentrated by spin column purification (Qiagen). The concentrated PCR products were 
resolved on 1% agarose gels and ≈400bp barcoded products excised and gel purified using a 
QIAquick gel extraction kit (Qiagen). The HAP1 libraries were sequenced using an Illumina 
MiSeq with 300-cycle (V2), paired-end settings.  
3.3.12 Data Analysis 
The raw fastq data was uploaded to the Galaxy server and all subsequent processing conducted 
therein.  In brief, forward and reverse raw fastq files were collapsed into single datasets 
according to their respective i7 barcodes and subsequently split by their i5 forward barcodes into 
their respective individual samples. The reads were then filtered by size to remove all reads 
below 150bp and trimmed to recover the unique 10nt barcode. All trimmed read files were then 
filtered to remove any reads containing bases with a quality score less than 15. The processed 
reads were then aligned to all barcode sequences present in the mDHHC or hDHHC libraries 
using Bowtie2 with default settings. Read counts were then extracted using SAMtools.  
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3.4 Results 
3.4.1 Cloning of hDHHC Cpf1 Library  
The hDHHC CRISPR-Cpf1 library was cloned into pRC11 (pLenti-U6-DR-crRNA-
BsmbI(x2)/EFS-Puro-WPRE) from oligo arrays synthesized by Genescript using the methods 
described by Chow et al. Library coverage was assessed by 2nd-generation sequencing using the 
Illumina MiSeq platform. The extracted reads revealed nearly complete coverage of the 
originally designed library ( »95% overall) with no discrimination between arrays for loss of 
coverage. (Figure 19) The depth of coverage for nearly all crRNA arrays was found to be at or 
above a LOG2 (RPM) of 5 and nearly uniform with few over- and under-represented arrays. 
(Figure 20) 
 
Figure 19. Representation of crRNA arrays by type relative to original library design in hDHHC 
Cpf1 Library. 
Co
ntr
ol
SK
O
DK
O
0
2000
4000
6000
cr
R
N
A
C
ou
nt
Full
Actual
 57 
 
Figure 20. Representation of all crRNAs by count in reads-per-million in the human hDHHC 
Cpf1 library. 
3.4.2 Cloning of mDHHC Cpf1 Library  
The mDHHC CRISPR-Cpf1 library was cloned into pRC49 (pLenti-U6- DR-crRNA-BsmbI(x2)-
6T/EFS-Puro-2A-Fluc-2A-EGFP_NLS-WPRE) from oligo arrays synthesized by Genescript 
using identical methods to the previous library. 2nd-generation sequencing of the cloned library 
revealed a nearly identical level of coverage compared to the hDHHC library ( »93% overall) 
again, with no discrimination between arrays. (Figure 21) The distribution of the sequencing 
depth across all arrays revealed a greater proportion with representation at or above a LOG2 
(RPM) of 5 than what was observed for the human-specific library. (Figure 22) A comparison of 
the sequencing depth across all represented arrays between the two libraries however revealed 
little difference in either the average or variance of either. (Figure 23) 
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Figure 21.  Representation of crRNA arrays by type relative to original library design in 
mDHHC Cpf1 Library. 
 
Figure 22. Representation of all crRNAs by count in reads-per-million in the mouse mDHHC 
Cpf1 library. 
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Figure 23. Comparison of average library representation per unique array present in the 
synthesized hDHHC and mDHHC CRISPR Cpf1 libraries.  
 
3.4.3 HAP1 Screen for DHHC Functional Redundancy 
The hDHHC CRISPR library was transduced into HAP1 human haploid cells stably expressing 
AsCpf1. After 18 days, the cultures were collected, sequenced, and fold changes calculated. 
Plotting the fold changes of each crRNA array against its statistical p-value revealed a 
distribution that was little shifted away from the center with the exception of a number of arrays 
displaying large positive fold changes. When subdivided between the different array types little 
difference was observed between the single and double knockout arrays although their 
distributions did appear shifted from that of the nontargeting control arrays. (Figure 24) 
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Figure 24. Volcano plots of fold change differences for (clockwise) total screen, nontargeting 
arrays, single knockout arrays, and double knockout arrays of all recovered crRNA arrays from 
end of screen (T18) compared to start (T0). 
 
From these, statistically significant crRNAs exhibiting fold changes of +/- 2 were identified and 
selected for further analysis. Of the significant single KO arrays only sequences targeted to 
DHHC18 appeared to be depleted with any frequency. Average fold changes were calculated for 
all single KO arrays targeted to DHHC18. (Figure 25)  
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Figure 25. Average log2 fold change distributions of all single targeting crRNA arrays for 
DHHC18. 
 
 No significant variation was observed for any of DHHC18-targeted arrays compared to the non-
targeting controls. With no other significant drop-outs observed for the remaining DHHCs, the 
SKO arrays for DHHCs exhibiting positive fold changes were then investigated. Plotting the 
average fold changes for all SKO arrays targeted to each significant DHHC again showed little 
variation from the non-targeting arrays. (Figure 26) 
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Figure 26. Average log2 fold change distributions of all single targeting crRNA arrays for all 
DHHCs exhibiting enrichment over time course of screen. 
 
 Only arrays targeted to DHHCs 11 and 11B exhibited average positive fold changes although 
the low average fold-change and high variability lend doubt to the reliability of this observation. 
Double knockout arrays were then investigated. Average fold changes for arrays targeted to 
DHHCs within the same structural subfamilies were compared to their respective single 
knockout arrays. (Figure 27) DHHCs 9 and 14, and 3 and 7 showed no change over their 
respective single arrays. DHHCs 1 and 11, 13 and 17, and 18 and 19 showed slight average 
decrease over their single arrays whereas 5 and 8, and 2 and 20 exhibited more notable changes. 
None of these, however, were found to be significant over non-targeting arrays and so cannot 
provide evidence of functional redundancy between structurally similar DHHCs. 
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Figure 27. Average log2 fold change of all single targeting crRNA arrays for all DHHC 
subfamilies compared to duplex arrays. 
 
 Finally, to determine if these insignificant changes were due to inefficiency in Cpf1 or to an 
inherent lack of genetic sensitivity in the HAP1 cell model to DHHC KO, the single knockout 
arrays targeted to previously reported essential genes were investigated. The distribution of 
arrays targeted to essential genes was found to be little different to that of the nontargeting 
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little change between the single knockout arrays and the non-targeting controls. (Figure 29) This 
suggested that flaws in the design of the library or a lack of efficiency in AsCpf1 prevented the 
detection of a growth phenotype. 
 
 
Figure 28. Volcano plots of fold change differences for nontargeting and essential gene arrays, 
from end of screen (T18) compared to start (T0). 
 
 
Figure 29. Average log2 fold change of all single targeting crRNA arrays for previously 
validated essential genes. 
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3.5 Discussion 
Cpf1 offers many advantages over Cas9 for performing pooled genetic screens. Unlike Cas9, 
Cpf1 is capable of processing its own mature crRNAs from pre-crRNAs and does not require a 
tracrRNA to form an active complex capable of cutting genomic DNA. This allows for multiple 
crRNAs to be expressed in tandem from a single promoter and opens the possibility of creating 
multiple simultaneous targeted gene knockouts. This should, in principle make Cpf1 uniquely 
suited to combinatorial pooled genomic screens. Herein, we designed a duplex knockout library 
with sgRNAs targeted to all DHHCs expressed in the human genome to assess the prevalence of 
functional redundancy within this gene family. Prior to performing these screens, the efficiency 
of Cpf1 was assessed by western blot in MEF cells using single sgRNAs targeted to the 
thioesterase APT1. For each of the three sgRNAs tested a small but noticeable change was 
observed in the amount of APT1 present over sgRNAs that lacked a targeting sequence and this 
effect became more pronounced when multiple sgRNAs were employed. When Cpf1 was used in 
a pooled screen of HAP1 cells however, no significant change was observed for any DHHC for 
either single or double knockout arrays. There are three possible factors that may have 
contributed to this negative result. Although DHHCs are known to palmitoylate many proteins 
involved in cellular growth it is possible that the knockout of one or more DHHCs may not be 
sufficient to create a noticeable deficiency in the growth of the affected cell. While this is 
certainly conceivable, and every effort should be made when performing genomic screens to use 
a strictly controlled genetic model, it is unlikely as the same absence of a phenotype was 
observed for sgRNAs targeted to essential genes determined from screens performed across 
multiple cell models. Although it has been extensively investigated in Cas9, little is known about 
the principles that determine the efficacy of sgRNAs for Cpf1. Here, we selected 3-4 sgRNAs for 
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each targeted gene based solely on their position in the coding sequence and their off-target score 
(likelihood of cutting at locations other than the intended target). While unlikely, it is possible 
that the sequences selected lacked sufficient activity toward their targets to affect a noticeable 
phenotype. A systematic investigation into the rules that govern Cpf1 sgRNA activity is certainly 
needed to ensure efficient editing of target genes. The final possibility is that Cpf1 lacks the 
necessary efficiency to generate sufficient gene knockouts to be observed in a genetic screen. 
Recently, Liu et al.127 performed a systematic study of AsCpf1 pooled genetic screens. Here, 
they found that the commonly used AsCpf1 variant (the same used here) consistently failed to 
generate separation between validated essential and non-essential genes in a pooled genetic 
screen despite showing no deficiency in generating indels from individual constructs. This effect 
was remedied by employing an AsCpf1 variant containing a 3x MYC NLS, revealing that the 
previously noted inefficiency of Cpf1 compared to Cas9 may be due in part to inefficient nuclear 
translocation. Furthermore, they found that the knockout efficiency improved when constructs 
containing multiple sgRNAs to a particular gene were used. While the constructs here contained 
sgRNAs targeted to different genes this might explain, in part, why double knockout arrays 
seemed to outperform their single knockout counterparts although even these differences were, at 
best, marginal. It would be of interest to repeat these screens using this optimized Cpf1 to see if 
this remedies the inefficiencies observed here. Presuming that the failure of our screens derives 
entirely from insufficient activity by Cpf1 it would be reasonable to expect that a repetition of 
these would yield a significant depletion phenotype at least for crRNAs targeted to essential 
genes. As a preliminary to these repeat screens, expression vectors identical to those contained in 
the libraries could be individually cloned and introduced into their respective cell models to 
assess them for gene-dependent growth depletion and provide assurances that this new Cpf1 
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variant is operating as expected. These vectors would contain the singly and doubly targeted 
arrays to essential genes or Ras isoforms present as controls in the hDHHC and mDHHC 
libraries respectively and would provide unambiguous validation of Cpf1 as well as evidence of 
the impact of double verses single crRNA on the knockout efficiency of the gene targeted. 
Should the growth assays for individual essential genes and the HAP1 screen provide good 
evidence of proper screen function we could then proceed to our original experimental aims and 
perform our screens for functional redundancy in Rasless MEFs using the mDHHC library. 
Should these preliminary experiments show otherwise and Cpf1 3x Myc NLS fail to sufficiently 
correct these problems, a redesign of the crRNA libraries would then need to be undertaken. As 
previously stated, Liu et al.127 found that the sensitivity of Cpf1 CRISPR screens only 
approached that of Cas9 when three crRNAs targeted to the same gene were expressed in tandem 
from a single expression vector. This suggests that randomizing single crRNAs targeting 
different genes into duplex arrays may be insufficient to generate a detectable phenotype and 
present an additional obstacle to proper screen function. To amend this issue, the libraries will be 
redesigned using randomized gene blocks (2-3 crRNAs targeted to a single gene) in place of 
single crRNAs, resulting in the expression of 4-6 crRNAs directed against two different genes 
for each expression vector. (Figure 30) The differences in observed Cpf1 activity with 
increasing numbers of crRNAs per gene block should be first evaluated using single expression 
vectors containing crRNAs directed against select essential genes prior undertaking a complete 
redesign of CRISPR libraries.  
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Figure 30. An alternative approach to the design of duplex CRISPR-Cpf1 knockout libraries 
involves the use of randomized blocks of crRNAs targeted to the same gene in place of single 
crRNAs. 
 
Once designed and assembled, these improved CRISPR-Cpf1 knockout libraries will then be 
employed in our human and, ultimately, MEF cell models to assess the extent of functional 
redundancy in DHHC palmitoyltransferases. An alternative approach that may be used in support 
or in place of these Cpf1 screens as necessary would make use of selective enrichment of 
palmitoylated proteins and LC-MS proteomics to assess the substrate profiles of individual 
DHHC PATs and determine where they are unique and where they overlap. The overexpression 
and/or knockout of single DHHCs can be undertaken in metabolically labeled cell culture128 and 
the isotopically-labeled proteomes enriched for palmitoylated proteins using acyl resin-assisted 
capture (acyl-RAC).129 (Figure 31) A panel of palmitoylated substrates could then be determined 
for each palmitoyltransferase by quantifying changes in palmitoylation relative to catalytic dead 
(overexpression) or wild-type (knockout) controls. If redundancy exists between PATs as 
expected, it would appear in the form of shared substrates. This approach would provide a 
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straightforward answer to the question of functional redundancy and, furthermore, would provide 
a more comprehensive analysis of the native substrates for every DHHC investigated. 
              
Figure 31. Acyl resin-assisted capture may be used to enrich for palmitoylated proteins for 
further proteomic study. Free thiols are first blocked by covalent modification after lysing the 
cells. Palmitoylated thiols are then cleaved with hydroxylamine and the now-free thiols captured 
with a thiol resin. The captured proteins may then be collected and prepared for proteomic 
analysis. 
 
3.6 Conclusions 
Questions surrounding the existence of functional redundancy between DHHC family 
palmitoyltransferases have yet to be systematically addressed. Herein, we attempted to 
investigate the extent of functional redundancy between DHHC family palmitoyltransferases by 
performing multiplex CRISPR-Cpf1 genetic screens. Duplex libraries targeting all know DHHC 
proteins in mice and humans respectively were successfully designed and cloned into lentiviral 
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expression vectors. Initial attempts to use these libraries in pooled screens however failed to 
uncover a significant depletion phenotype even in those arrays targeted to essential genes that 
had been previously validated. Recently published literature suggests that the suboptimal 
performance of these screens may be due either to insufficient activity of commonly used Cpf1 
variants or an insufficient number of crRNAs included into each expression vector. Newer Cpf1 
variants have since been engineered to address issues surrounding Cfp1 activity in pooled 
screens and should be tested with the CRISPR libraries designed here to assess whether a 
complete redesign is necessary to achieve the intended experimental aims. Once proper screen 
function is confirmed after making the necessary changes, screens should be performed in 
appropriate human and mouse cell models supported by DHHC overexpression/knockout LC-
MS proteomics to provide a comprehensive assessment of PAT functional redundancy, substrate 
specificity, and the site-specific palmitoylation of protein substrates. 
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Chapter 4 
Conclusions and Future Directions 
 
4.1 Overview of Experimental Outcomes 
Herein, we attempted to use CRISPR pooled genetic screens to identify the necessary 
components of the cellular oxidative stress response and investigate the question of functional 
redundancy between structurally similar DHHC-family acyltransferases. The first of these was 
accomplished in part using the Cas9 TkOv1 pooled CRISPR library although the small number 
of identified hits and the lack of known functional uniformity between them suggests that many 
of these may be false positives created by insufficient genotoxic stress of the hydrogen peroxide 
treatment used. The second question, unfortunately, remains completely unresolved by our 
efforts, accomplished here by employing a custom Cpf1 duplex CRISPR library. This is most 
likely due to inefficiency in the activity of AsCpf1 to induce sufficient indels necessary to 
achieve a discernable phenotype in the context of a pooled screen. This effect was noted by Liu 
et al.127 in their recent comprehensive study of Cpf1-CRISPR pooled screens and was attributed 
to inefficient nuclear localization of commonly employed AsCpf1 variants. Indeed, they found 
that this inefficiency was almost entirely corrected by employing a novel 3x Myc-tagged AsCpf1 
variant such that it’s performance in pooled knockout screens approached that of Cas9. Although 
our primary research aims were not accomplished using these approaches they do, however, 
provide lessons in the design and use of CRISPR systems for both single and genome-wide 
knockout that may be of use to others intending to use these methods. Herein, we will summarize 
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what may be considered best practices for using CRISPR methods drawing on the current 
literature and supplemented by our own experiences. 
4.2 Considerations for Optimal crRNA Design 
Efficient gene editing using CRISPR requires that the sgRNAs used consistently guide the 
nuclease complex to its gene target and induce cutting. Ideal sgRNAs should induce efficient 
cleavage at their target location while not creating off-target cleavages at other regions within the 
genome. Several studies into the factors that determine sgRNA efficiency have been conducted 
and from these a series of rules have been determined for the design of sgRNAs. For Cas9 
sgRNAs, the composition of the targeting sequence and the sequence of the PAM have been 
shown to have the greatest influence on activity. Of the 20bp targeting sgRNA, the 8-14bp 
region proximal to the PAM have been found to be essential to activity with even single 
mismatches resulting in a significant reduction in activity at the intended target site and a 
concurrent increase in off-target activity; the distal regions, by contrast, had much less influence 
on activity.128 The activity of sgRNAs was further influenced by nucleotide composition, gRNA 
location within the protein, and DNA melting temperature.129 The optimal PAM sequence has 
been repeatedly show to be 5’-NGG with sgRNAs possessing a C at the first position exhibiting 
the highest activity those possessing a T the lowest.130 These design factors have been 
incorporated into a number of algorithms to confidently identify sgRNAs with high activity.131 
For the selection of sgRNAs, it would be advisable to select previously validated sequences, 
however this is only possible for a small subset of genes. In these situations, it is recommended 
that these validated scoring algorithms be used to identify sgRNAs that possess both high 
activity and exhibit low off-target activity. Furthermore, it has been shown that the region within 
a gene targeted by the sgRNA has little effect on its activity with the exception of the C-
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terminus.132 This encourages the selection of sgRNAs spaced across the length of target gene to 
improve the number of options for selecting sgRNAs with high activity and specificity. To date, 
no systematic study of Cpf1 sgRNA activity comparable to Cas9 has been conducted and so it is 
uncertain what differences, if any, exist between these two systems. Elucidation of these Cpf1-
specific design principles will be necessary to maximizing the advantages offered by this system. 
To mitigate potential issues with the selection of Cpf1 sgRNAs with low activity multiple 
sgRNAs should be selected for each target gene, spaced across the length of the coding 
sequence.  
 
4.3 Considerations for Optimal CRISPR Screen Design 
Effective genomic screening with CRISPR requires that a balance be maintained between library 
complexity and the scale of the proposed screen. Early CRISPR libraries required large numbers 
of sgRNAs be employed for each gene to increase sensitivity by circumventing unknown sources 
of inefficiency. When this strategy was applied for whole-genome screens, the resulting library 
complexity required high numbers of cultured cells to maintained sufficient library coverage for 
the screen to function properly. This imposed technical limitations on the scale of the screens and 
the cell models that could be employed in them and therefore, the questions that could be 
answered using CRISPR screens. A better understanding of the principles that govern sgRNA 
activity permitted a reduction in the number of sgRNAs necessary to effectively perform whole 
genome screens. This was aptly demonstrated by Hart et al. in the design of their TKOv3 
CRISPR library where the library size was reduced from 176,500 to 71,090 sgRNAs over their 
TKOv1 library while significantly improving library performance.133 Library complexity can be 
further reduced when the questions being investigated necessitate that only single class or subset 
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of genes be employed in the screen. This has been done to create Cas9 libraries for metabolic 
genes, kinases, and DNA-binding domain proteins among others at a fraction of the library size 
required for whole-genome screening.134,135 When designing pooled CRISPR screens for Cas9, it 
is therefore important to carefully consider the question the screen is intended to answer so as to 
appropriately design the library with the minimum requisite complexity for the scope of the 
screen to be performed. The unique ability of Cpf1 to process multiple crRNAs from single 
arrays provides for improved flexibility in screen design over Cas9. This feature not only permits 
screening of combinatorial interactions between different genes but can also be used to further 
reduce the complexity of whole-genome libraries without sacrificing sensitivity. This was aptly 
demonstrated by Liu et al. in their design of a multiplex AsCpf1 library where 2,061 distinct 
guides were assembled into 687 library constructs by combining all guides targeted to a 
particular gene into a single three guide array.127 This library showed comparable performance to 
an identical mono-cistronic Cas9 library of 2,061 constructs. Interestingly, these two libraries 
significantly outperformed an identical mono-cistronic AsCpf1 library suggesting that AsCpf1 
requires multiple crRNAs to be expressed simultaneously to induce efficient gene editing when 
used in pooled screens. This raises questions about the sensitivity of AsCpf1 when used to screen 
combinatorial interactions between different genes; it may be necessary to pair 2-3 guide arrays 
targeted to each gene in order to reproduce the efficiency demonstrated here for the screening of 
single genes.   
 
4.4 General Guidelines for CRISPR Genomic Screen Design 
The importance of careful library design cannot be understated when using CRISPR pooled 
screens to investigate biological phenomena. Our experiences working with CRISPR pooled 
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screens have demonstrated that equal consideration should be given to the implementation of the 
screen itself. Here, particular consideration is given to cell model used in the screen. In both our 
Cas9 and Cpf1 screens we employed a nearly haploid human HAP1 cell line. This cell line 
grows to high density and was aptly suited to whole genome knockout screens particularly those 
performed with the larger first generation CRISPR libraries. Although it was not the primary 
cause of our Cpf1 screens failure, it must be pointed out that the DHHC-family proteins targeted 
by the screen may not have been sufficiently important to cell survival to induce a detectable 
phenotype in this cell line. A better approach would have been to employ a cell line with a 
carefully controlled growth dependency such as that present in the Rasless MEF cell lines that 
were briefly used herein. Similarly, when the genetic components of a particular stressor are 
being investigated compared to an untreated population it is critical that the treatment exert its 
effects through a defined mechanism of action. This is aptly demonstrated by the early CRISPR 
KO screens performed using cytotoxic drugs such as vemurafenib.136 These stressors operate 
through a defined mechanism and so yielded unambiguous phenotypes that were easily detected 
by CRISPR knockout screens. In our own screens, we employed a hydrogen peroxide solution 
applied by daily bolus dose as a source of oxidative stress. This was necessary for want of better 
methods for creating conditions of oxidative stress in cell culture. This may not have been 
sufficient however in specificity or duration to parse out a defined genetic phenotype. Hydrogen 
peroxide induces indiscriminate cell damage and the dosing method used here may have simply 
induced necrotic cell death independent of the underlying genetic background leading to an 
abundance of false positives. A better approach would have been knockout some essential 
component of redox homeostasis such as glutathione cycling so as to induce a constitutive state 
of oxidative stress. In this genetic model, subsequent knockout of other essential components of 
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redox homeostasis by CRISPR would be unsustainable and lead to a lethal phenotype. These 
considerations should be taken into account should this or similarly indiscriminate stressors be 
used in the context of a pooled genomic screen. 
 
4.5 Conclusions 
Although our experiences using CRISPR genetic knockout screens did not yield answers to the 
questions that we intended to investigate there are abundant lessons to be drawn from them on 
the proper implementation and limitations of CRISPR methods. It is our hope that the above 
discussion of CRISPR screen design and implementation will help guide the work of others to a 
successful outcome. These methods have been, from the time of their discovery to the present, in 
a state of constant development. They will continue to be refined and applied to new questions. 
They will certainly lead to new insights beyond the reach of the methods that preceded them and 
push the boundaries of our understanding of life itself.    
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APPENDIX A 
 
Cloning, Expression and Validation of pCLHCX-AsCpf1 
To circumvent potential problems with expression of the Cpf1 nuclease in MEF cell models 
already under blastocidin (HRas isoforms) and puromycin selection (gRNA libraries), AsCpf1 
was subcloned into a pCLHCX vector containing a hygromycin selection cassette. Primers 
specific to AsCpf1 containing Hindiii and NotI restriction sites were used to amplify the gene 
from pY108 (Addgene #84739).  
The following primers and conditions were used: 
pCL-AsCpf1_F : 
TTTAAGCTTGCCACCATGGCCCCAAAGAAGAAG 
 
pCL-AsCpf1_R: 
TTTGCGGCCGCCTTTTTCTTTTTTGCCTGGC 
 
Plasmid DNA :     100ng 
MgCl2 (50mM) :     1μL 
dNTP Mix (10mM):    1μL 
pCL-AsCpf1_F :(10μM)   2.5μL  
pCL-AsCpf1_R (10μM)   2.5μL 
Phusion Buffer (5x):    10μL 
Phusion High-Fidelity Polymerase (NEB): 1μL 
diH2O:      to 50μL 
 
Thermocycler conditions: 
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1. 98°C 1min. 
2. 98°C 30s. 
3. 55°C 30s. 
4. 74°C 20s.  è repeat steps 2-4 for 34 cycles 
5. 74°C 10min. 
6. 4°C ∞ 
 
The PCR product was confirmed by running the reaction on a 1% agarose gel (≈4400 bp 
amplicon) and extracted with a QIAquick Gel Extraction Kit. 
 
The pCLHCX parent vector and AsCpf1 insert were then restriction digested to generate 
compatible ends for ligation: 
Plasmid DNA :     1μg 
Gene Insert :     500ng 
Hindiii      1μL  
NotI      1μL 
NEB Cutsmart Buffer (10x)    10μL 
diH2O:      to 50μL 
 
The digest was allowed to run for 90 minutes at 37oC and collected using a Zymo DNA 
concentrator column and following the manufacturer’s instructions. The purified Cpf1 fragment 
was then ligated into the linearized pCLHCX vector: 
 
Plasmid DNA :     50ng 
Gene Insert :     25ng 
T4 DNA Ligase Buffer (5x)    10μL 
T4 DNA Ligase(Thermo)   1μL   
diH2O:      to 50μL 
 
The ligation was allowed to run overnight and the assembled vector collected using a Zymo 
DNA concentrator column. The ligated vectors were then transformed into Stbl3 
electrocompetent cells and colonies selected for validation. Once cloning of AsCp1was 
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confirmed, it was packaged into retrovirus and used to transduce HRas-dependent MEF cell lines 
to confirm expression and activity. Anti-His 6x western blot of cell lysates reveled expression a 
single protein at the expected molecular weight of »165kDa. Single gRNAs targeted to cellular 
thioesterase APT1 were cloned into pU6-sgRNA EF1Alpha-puro-T2A-BFP (Addgene #60955) 
and stably transduced into MEF-HRas cultures expressing AsCpf1 along with a control lacking a 
targeting sequence. Western blot of APT1 was then used to assess the efficacy of AsCpf1. 
 
 
 
 
  
MEF MEF CPF1 
NT APT1_1 APT1_2 APT1_3 APT1_1,2,3 
150- 
50- 
25- 
APT1 
Tubulin 
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APPENDIX B 
 
 
PCR Primers for Illumina Library Preparation 
 
Toronto Knockout Library (TKOv1) 
Nested PCR Step One primer sequences  
Outer Primer Forward: AGGGCCTATTTCCCATGATTCCTT  
Outer Primer Reverse: TCAAAAAAGCACCGACTCGG  
Nested PCR Step Two primer sequences 
Illumina True seq adapters with i5 barcodes  
Forward 1: 
AATGATACGGCGACCACCGAGATCTACACTATAGCCTACACTCTTTCCCTACACGA
CGCTCT TCCGATCTTGTGGAAGGACGAGGTACCG  
Forward 2: 
AATGATACGGCGACCACCGAGATCTACACATAGAGGCACACTCTTTCCCTACACGA
CGCTCT TCCGATCTTGTGGAAGGACGAGGTACCG  
Forward 3: 
AATGATACGGCGACCACCGAGATCTACACCCTATCCTACACTCTTTCCCTACACGA
CGCTCT TCCGATCTTGTGGAAGGACGAGGTACCG  
Forward 4: 
AATGATACGGCGACCACCGAGATCTACACGGCTCTGAACACTCTTTCCCTACACGA
CGCTCT TCCGATCTTGTGGAAGGACGAGGTACCG  
Illumina True seq adapters with i7 barcodes  
Reverse 1: 
CAAGCAGAAGACGGCATACGAGATCGAGTAATGTGACTGGAGTTCAGACGTGTGCT
CTTCC GATCTATTTTAACTTGCTATTTCTAGCTCTAAAAC  
Reverse 2: 
CAAGCAGAAGACGGCATACGAGATTCTCCGGAGTGACTGGAGTTCAGACGTGTGCT
CTTCC GATCTATTTTAACTTGCTATTTCTAGCTCTAAAAC 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Reverse 3: 
CAAGCAGAAGACGGCATACGAGATAATGAGCGGTGACTGGAGTTCAGACGTGTGC
TCTTCC GATCTATTTTAACTTGCTATTTCTAGCTCTAAAAC  
Reverse 4: 
CAAGCAGAAGACGGCATACGAGATGGAATCTCGTGACTGGAGTTCAGACGTGTGCT
CTTCC GATCTATTTTAACTTGCTATTTCTAGCTCTAAAAC  
Reverse 5: 
CAAGCAGAAGACGGCATACGAGATTTCTGAATGTGACTGGAGTTCAGACGTGTGCT
CTTCCG ATCTATTTTAACTTGCTATTTCTAGCTCTAAAAC  
Reverse 6: 
CAAGCAGAAGACGGCATACGAGATACGAATTCGTGACTGGAGTTCAGACGTGTGCT
CTTCC GATCTATTTTAACTTGCTATTTCTAGCTCTAAAAC  
Red: barcode 
Bold: constant vector region  
Index keys for sequencing sample submission sheet:  
  I5 Index  
 
I5 Index for 
Submission 
  I7 Index  I7 Index for 
Submission 
F1 D501 TATAGCCT TATAGCCT R1 D701 CGAGTAAT ATTACTCG 
F2 D502 ATAGAGGC ATAGAGGC R2 D702 TCTCCGGA TCCGGAGA 
F3 D503 CCTATCCT CCTATCCT R3  D703 AATGAGCG CGCTCATT 
F4 D504 GGCTCTGA GGCTCTGA R4  D704 GGAATCTC GAGATTCC 
F5 D505 AGGCGAAG AGGCGAAG R5 D705 TTCTGAAT ATTCAGAA 
F6 D506 TAATCTTA TAATCTTA R6 D706 ACGAATTC GAATTCGT 
 
 
mDHHC/hDHHC Dual Knockout Libraries 
 
Nested PCR Step One primer sequences  
Outer Primer Forward (DHHC_vrd1_F):  
AATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCG 
Outer Primer Reverse (DHHC_vrd1_R):   
CTTTAGTTTGTATGTCTGTTGCTATTATGTCTACTATTCTTTCCC 
Nested PCR Step Two primer sequences 
Illumina Forward Adapter Sequences  
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Forward 1:  
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATC
TTAAGTAGAGTCTTGTGGAAAGGACGAAACACCG 
 
Forward 2:  
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATC
TATACACGATCTCTTGTGGAAAGGACGAAACACCG 
 
Forward 3:  
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATC
TGATCGCGCGGTTCTTGTGGAAAGGACGAAACACCG 
 
Forward 4: 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATC
TCGATCATGATCGTCTTGTGGAAAGGACGAAACACCG 
  
Forward 5: 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATC
TTCGATCGTTACCATCTTGTGGAAAGGACGAAACACCG 
 
Forward 6: 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATC
TATCGATTCCTTGGTTCTTGTGGAAAGGACGAAACACCG 
 
Forward 7: 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATC
TGATCGATAACGCATTTCTTGTGGAAAGGACGAAACACCG 
 
Forward 8: 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATC
TCGATCGATACAGGTATTCTTGTGGAAAGGACGAAACACCG 
 
Forward 9: 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATC
TACGATCGATAGGTAAGGTCTTGTGGAAAGGACGAAACACCG 
 
Forward 10: 
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AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATC
TTAACAATGGTCTTGTGGAAAGGACGAAACACCG 
 
 
 
 
Forward 11: 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATC
TATACTGTATC TCTTGTGGAAAGGACGAAACACCG 
 
Forward 12: 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATC
TGATAGGTCGCA TCTTGTGGAAAGGACGAAACACCG 
 
Illumina Reverse Adapter Sequences  
Reverse 1:  
CAAGCAGAAGACGGCATACGAGATAAGTAGAGGTGACTGGAGTTCAGACGTGTGCT
CTTCCGATCTTTCTACTATTCTTTCCCCTGCACTGT 
 
Reverse 2:  
CAAGCAGAAGACGGCATACGAGATACACGATCGTGACTGGAGTTCAGACGTGTGCT
CTTCCGATCTATTCTACTATTCTTTCCCCTGCACTGT 
 
Reverse 3:  
CAAGCAGAAGACGGCATACGAGATCGCGCGGTGTGACTGGAGTTCAGACGTGTGCT
CTTCCGATCTGATTCTACTATTCTTTCCCCTGCACTGT 
 
Reverse 4:  
CAAGCAGAAGACGGCATACGAGATCATGATCGGTGACTGGAGTTCAGACGTGTGCT
CTTCCGATCTCGATTCTACTATTCTTTCCCCTGCACTGT 
 
Reverse 5:  
CAAGCAGAAGACGGCATACGAGATCGTTACCAGTGACTGGAGTTCAGACGTGTGCT
CTTCCGATCTCGATCTCTACTATTCTTTCCCCTGCACTGT 
 
Reverse 6:  
CAAGCAGAAGACGGCATACGAGATTCCTTGGTGTGACTGGAGTTCAGACGTGTGCT
CTTCCGATCTTTCTACTATTCTTTCCCCTGCACTGT 
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Reverse 7:  
CAAGCAGAAGACGGCATACGAGATAACGCATTGTGACTGGAGTTCAGACGTGTGCT
CTTCCGATCTATTCTACTATTCTTTCCCCTGCACTGT 
 
 
Reverse 8:  
CAAGCAGAAGACGGCATACGAGATACAGGTATGTGACTGGAGTTCAGACGTGTGCT
CTTCCGATCTGATTCTACTATTCTTTCCCCTGCACTGT 
 
Reverse 9:  
CAAGCAGAAGACGGCATACGAGATAGGTAAGGGTGACTGGAGTTCAGACGTGTGCT
CTTCCGATCTCGATTCTACTATTCTTTCCCCTGCACTGT 
 
Reverse 10:  
CAAGCAGAAGACGGCATACGAGATAACAATGGGTGACTGGAGTTCAGACGTGTGCT
CTTCCGATCTCGATCTCTACTATTCTTTCCCCTGCACTGT 
 
Reverse 11:  
CAAGCAGAAGACGGCATACGAGATACTGTATCGTGACTGGAGTTCAGACGTGTGCT
CTTCCGATCTTTCTACTATTCTTTCCCCTGCACTGT 
 
Reverse 12:  
CAAGCAGAAGACGGCATACGAGATAGGTCGCAGTGACTGGAGTTCAGACGTGTGCT
CTTCCGATCTATTCTACTATTCTTTCCCCTGCACTGT 
 
Red: barcode 
Bold: constant vector region  
 
 
Nested PCR hDHHC Step One primer sequences  
Outer Primer Forward (DHHC_vrd1_F):  
AATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCG 
Outer Primer Reverse (hDHHC_R1):   
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GTAATTCTTTAGTTTGTATGTCTGTTGCTATTATGTCTACTATTC 
 
Illumina hDHHC Forward Adapter Sequences  
Forward 1:  
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATC
TTAAGTAGAGTCTTGTGGAAAGGACGAAACACCG 
 
Forward 2:  
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATC
TATACACGATCTCTTGTGGAAAGGACGAAACACCG 
 
Forward 3:  
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATC
TGATCGCGCGGTTCTTGTGGAAAGGACGAAACACCG 
 
Forward 4: 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATC
TCGATCATGATCGTCTTGTGGAAAGGACGAAACACCG 
  
Forward 5: 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATC
TTCGATCGTTACCATCTTGTGGAAAGGACGAAACACCG 
 
Forward 6: 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATC
TATCGATTCCTTGGTTCTTGTGGAAAGGACGAAACACCG 
 
Forward 7: 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATC
TGATCGATAACGCATTTCTTGTGGAAAGGACGAAACACCG 
 
Forward 8: 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATC
TCGATCGATACAGGTATTCTTGTGGAAAGGACGAAACACCG 
 
Forward 9: 
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AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATC
TACGATCGATAGGTAAGGTCTTGTGGAAAGGACGAAACACCG 
 
Forward 10: 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATC
TTAACAATGGTCTTGTGGAAAGGACGAAACACCG 
 
Forward 11: 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATC
TATACTGTATC TCTTGTGGAAAGGACGAAACACCG 
 
Forward 12: 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATC
TGATAGGTCGCA TCTTGTGGAAAGGACGAAACACCG 
 
Illumina hDHHC Reverse Adapter Sequences  
Reverse 1:  
CAAGCAGAAGACGGCATACGAGATAAGTAGAGGTGACTGGAGTTCAGACGTGTGCT
CTTCCGATCTTTTATGTCTACTATTCTTTCCCCTGC 
 
 
Reverse 2:  
CAAGCAGAAGACGGCATACGAGATACACGATCGTGACTGGAGTTCAGACGTGTGCT
CTTCCGATCTATTTATGTCTACTATTCTTTCCCCTGC 
 
Reverse 3:  
CAAGCAGAAGACGGCATACGAGATCGCGCGGTGTGACTGGAGTTCAGACGTGTGCT
CTTCCGATCTGATTTATGTCTACTATTCTTTCCCCTGC 
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APPENDIX C 
 
 
zDHHC sgRNA Sequences 
 
zDHHC sgRNA 
# 
Strand Sequence PAM 
zDHHC1 
1 + GGGTCCTTGTTCCCCTCTTG TTTG 
2 + CTGGCCACCTTGTGGTGCAC TTTG 
3 - GATCGCGCACTCACGTCCAC TTTG 
4 + TACACAGTGTGGCATCTGCT TTTC 
zDHHC2 
1 - CCATGGACACTATGCACAGC TTTC 
2 - CCAGTATGACCAGACAAACA TTTT 
3 - GCTGCTCGCCTCAGAACTTC TTTG 
4 - TCACAGACGGAACAATGATG TTTA 
zDHHC3 
1 - CGCTCAATGTCTCGGAAGTG TTTC 
2 + TCCGAGATGGCTGTGGCATT TTTA 
3 + TCATGCTGGTTCCATCCCGA TTTG 
4 - GGCACTGCCCCGGGGTCCGT TTTG 
zDHHC4 
1 - GTGAAGATGCAGATCAGGAC TTTT 
2 + AAGGCCGTGGTCCTTGGAGG TTTG 
3 - GTGATGGTACCAGGATTGGC TTTA 
4 + AGGAAACCAGCCCGCTCCAA TTTA 
zDHHC5 
1 - AACCTCTTTCCAGACTCTGC TTTG 
2 + CGTGTCCAGGACTAAGCCTG TTTA 
3 + CCCGAGCCGAGGAAGATGAA TTTC 
4 + CCGCCCTCCTAGATGCTCCC TTTA 
zDHHC6 
1 - CAAACTTGATTACTGAGCAG TTTT 
2 + CCGCCACCTTGTTTGCCTTG TTTG 
3 - GCCTTTTCTTCAATCCATGA TTTA 
4 + CATGGTCGGGAGTTCCTGAA TTTA 
zDHHC7 
1 - GGGACAGCACCCGGGTCAGT TTTG 
2 + CAAGAGATGCATTCGAAAGA TTTG 
3 + ACCATGTACATAGCTCTGTC TTTC 
4 - ATCATTGCATATCGAGTGGA TTTC 
zDHHC8 
1 - AGGCGCGTCCCGGGGCTGCG TTTG 
2 + TCCTGGCCAACTTCAGTATG TTTG 
3 + ACCGTCCACCGCGCTGCTCA TTTT 
4 + ACCATCACTGCCCCTGGGTC TTTG 
zDHHC9 1 - CGTGTCACCTTCTTTCTTAC TTTC 
 101 
2 - CCGGGCCATCATGACGCGGC TTTG 
3 + CCTTCGAGTGTCGCTACCTG TTTG 
4 - TCTGGAAATTCTTAATACGA TTTA 
zDHHC11 
1 - CTGGGCTTCTGGGAGGACCC TTTC 
2 + AGGCAATATCCTGGATCACC TTTC 
3 - GCTTTTTTGCTCGCGGTAAC TTTG 
4 - CAGTGGTGGTCAAAGCCAGA TTTG 
zDHHC12 
1 + GCCGCCGCTTAACTCTGGGA TTTG 
2 + TCTGGCTGTGTCACTCATGG TTTA 
3 + TGGCCTACCTGGCACTGCAG TTTG 
4 - GAGTCGGCCCTCGGTCAAAG TTTC 
zDHHC13 
1 - TCCCTTAGCATTTCGGATGT TTTC 
2 + CAAGGTTTTTGGTTGGCTAT TTTC 
3 + GCACATCATGTCTTATAAGG TTTT 
4 + ATCAGCACTGCTTTTGGACT TTTG 
zDHHC14 
1 - ATGGGCCCGCCGCCGCCGGG TTTC 
2 - CTCCGGGCCGCGATTTTCTT TTTC 
3 + GCAACGGGAGGATCATGATG TTTT 
4 - ACGGTCTGGCCATTGATGAC TTTC 
zDHHC15 
1 + AACTCTGCCTGGTGACTGTT TTTG 
2 - ATAGCGCTCCTTGTCTGTAT TTTT 
3 - AAACACACATGGCACAGACA TTTA 
4 - TAGTTGGAAAATCCAATGCA TTTG 
zDHHC16 
1 + GCTCCTGGGCTACCGGCGTC TTTT 
2 + CCTGCGCTCCCTGCTCTACA TTTG 
3 + GAGTGGTGTTTGTGGTGCTG TTTG 
4 - GCCAGGGGCAGTGATGATCC TTTA 
zDHHC17 
1 - GCTATACAGCGGTTGCACAC TTTG 
2 + TGCCGAAATTCCTTGTCAGC TTTA 
3 - GTCAAATACTATATTTCGAA TTTC 
4 - ATTTCCTCCGGGTGGAGAAG TTTC 
zDHHC18 
1 + ACGGACCCTGGCATCCTGCC TTTC 
2 - ACTGTCTGCCCGTTGATCAT TTTC 
3 + GGCCTCCCCGGACCTCGCAC TTTC 
4 - ATATCTTCGTTAGTTGTCAG TTTG 
zDHHC19 
1 + ATGGTTCCCCTCGAGCGTGT TTTC 
2 + TTCGGATTCCCTTGTAGGTG TTTC 
3 - GTGGAGCCTCGATGTAAGAT TTTG 
4 + CGTGGAGGACTTCGACCACC TTTG 
zDHHC20 
1 + TGGTCGTCTGGTCCTACTAC TTTG 
2 + CAGAACAGGAGAGAAAGGAA TTTC 
3 - ACAAGTAGAACTCTTTGGAA TTTG 
4 - TCACAATATCGGATAGCCTT TTTT 
zDHHC21 1 + TTGTTGACCCGCATGGTTGG TTTG 2 + CTCACTATGAAGAAGGACAT TTTC 
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3 + GCCTGGTTGCCTTAGTGAGG TTTT 
4 - TCCAAGGACAGTGATGGTCC TTTA 
zDHHC22 
1 + CCTGGTGACCTTCGTACTGC TTTC 
2 + TTCACCGGCAACTGCATCGG TTTC 
3 + CTCCATGGTGGCTGGAGTGG TTTA 
4 + CTGTCGGCCTGGCCTGCGCC TTTG 
zDHHC23 
1 - TTTTTTTTGACTGGCTTCAT TTTC 
2 - GCAAGTCTCCGGCCGAAGTG TTTC 
3 - GACCGGGCATTCAATTTGGC TTTT 
4 - TCCAGACACAATGATGGTCC TTTA 
zDHHC24 
1 - GCACTGGTAACAGTAAGCCC TTTG 
2 - CCTGTGAGTAGCATGAGCCA TTTG 
3 + TGGTGGACACGTGTGTGGCA TTTG 
4 + CATGGGATGCTGCTGCTTCG TTTC 
zDHHC25 
1 + ACAATGTACATTGGACTTAC TTTC 
2 + TCCTCCTGGTGGCGATAATG TTTC 
3 + CCGTGGTGATGCTCTGCAGC TTTG 
4 - CGCACTTGGACCATCTGCCC TTTG 
 
 
Targeted Control sgRNAs 
 
Ras Isoform sgRNA # Strand Sequence PAM 
NRas 
1 - CTGTAAGAATCCTCTATGGT TTTT 
2 + TTGGACATACTGGATACAGC TTTG 
3 - CCACTAGCACCATAGGTACA TTTC 
4 - AATGAATGGAATCCCGTAAC TTTC 
HRas 
1 + GTGGACGAATACGACCCCAC TTTT 
2 + CCATCAACAACACCAAGTCT TTTG 
3 - ATCTGCTCCCTGTACTGGTG TTTG 
4 + GAGGACATCCACCAGTACAG TTTT 
KRas4a 
1 + GTGGACGAATATGATCCAAC TTTT 
2 - CTACTAGGACCATAGGTACA TTTC 
3 - AATCTGTATTGTCGGATCTC TTTC 
4 + TACATTGGTGAGGGAGATCC TTTA 
KRas4b 1 - 
TGTTTTCGAATTTCTCGAAC TTTA 
2 - TACCATCTTTGCTCATCTTT TTTT 
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Non-targeted Control sgRNAs 
 
# 0 10 20 30 40 50 
0 
 TATCGAA
CGCTATC
GAACGT 
CGCGACG
GCGGTTTT
AACAC 
TGGCGCG
TAATCGCT
ATTCG 
AGCGTCG
TACGATTT
ATCGT 
CGCCGAA
CGGATAA
GACTAT 
0
1 
TATAGCG
TCGCGCG
CTAATT 
TCCGGTTA
CGACCGG
CAAAA 
GTCGCGTT
GCGACCG
GCGCT 
CAACCCG
CCGTAGC
GGGCCT 
CGGAACG
CGTGATA
CTAGGG 
CGACCGA
GGTTACG
CTGGGA 
0
2 
CGCGTAA
CCGTTCC
GGCTCC 
CGTCGTA
GAACGAT
ACCCGA 
ACCGCTA
ATCGGCG
TAAACT 
TTTGCGTT
GACGCGA
TTACT 
AGCGGGT
CGTAGAC
GCGCGG 
ATCGCCG
TACGGCT
ATGGCA 
0
3 
CGCTAAG
TTCGCGC
GGGCCG 
TTATGTCG
CGCCGCG
ACCCG 
CGCGATC
TATACCGT
CTATA 
AACGGAG
CGCGATA
CTACCA 
TCTCGTAT
CGCGATT
GTTAA 
 
0
4 
CGTTCGTC
GACGAAG
CAATC 
ATTCCGG
CGCGACC
AGAAGA 
TCGACGC
GAGACGA
CGTACA 
CCGGACG
TTATAAC
GTTTCT 
CGGTCGA
CTACGGCT
GTTAG 
 
0
5 
GACCGTT
GTATCGC
GATCAA 
GTATAAC
TTCGCGC
GGTCCG 
CGATCGT
ACGGGTG
TCCTAA 
ATACCCG
TCGCGAA
CGTGAG 
TCGGGGC
GCGTCAA
CTGAAT 
 
0
6 
GACCGTT
GTATCGC
GATCAA 
GCGCGTC
AACGTAA
TGTGCC 
GCCGACC
GCGTGAT
TGTAGG 
ATTCGCG
AACCCGG
CCGGAA 
GCTTACGC
GTCGCGA
ATGTA 
 
0
7 
CCGTTCGT
GCGATAG
TGTTT 
ACGCGCT
ATTATCGT
AGGTG 
GCACGTT
ACGCCCG
GGTCAC 
TTGATGG
CGCGACG
CGTTAT 
ATTGCCGC
TCGCGCA
AAATC 
 
0
8 
GTTGTCGT
GCCGCGA
ATTTA 
ACTATCG
ACGTTCGT
CCCGG 
TAAGCGA
CCGACGC
ATTCGC 
GGTCAAA
TCGCGGC
GATAAC 
TAACGCG
CAACACG
CCAATG 
 
0
9 
CGGTACG
TTAGACG
AAAATT 
TCGCGTTA
TCGTGCC
GTGCG 
TAGCGTTC
GACACGT
GAAAC 
CGACTCG
CGCATTG
AACTGG 
CGAATCG
CGCCTAC
GGGAAT 
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APPENDIX D 
zDHHC sgRNA Sequences 
zDHHC sgRNA # Strand Sequence PAM 
zDHHC1 
1 + CTGTGATCGGCTTTGGGATC TTTG 
2 + GGATCCTTGTTCCCCTCCTG TTTG 
3 + CTGGCCACCTTGTGGTGCAC TTTG 
4 + GACCACCACTGCAAGTGGCT TTTC 
zDHHC2 
1 - CATGGACACTATGCACAGCT TTTC 
2 + GCAATGTTTGTCTGGTCATA TTTT 
3 - TAAGTTGGCATCTGTCACAG TTTA 
4 + TTGGAGAGAGAGCCAAGAGG TTTG 
zDHHC3 
1 - CGCTCAATGTTTCGGAAGTG TTTC 
2 - GGCACTGCCCCGGGGTCCGT TTTG 
3 + TCCGTGACGGCTGTGGCATC TTTA 
4 - GGGCACTTGTACACCACCTG TTTG 
zDHHC4 
1 - GAGCAGACGCAGATAAGAAC TTTC 
2 + CCATACGAGAAACCACACCT TTTT 
3 + TCACCCTGACTTGTGGAACC TTTT 
4 + AGGAAACCAGCTCGATCCAA TTTA 
zDHHC5 
1 + CGTGTCCAGGACTAAGCCTG TTTA 
2 + CCCTCGAGCTGAGGAGGATG TTTT 
3 + CGAGCTCCCCTTTACAAAAC TTTC 
4 + ACCGTCCCCCTCGATGTTCC TTTT 
zDHHC6 
1 - CAAACTTGATAACCGAACAG TTTT 
2 - CGGTTTCCACCCCAGAGGGA TTTC 
3 + TCCCTCTGGGGTGGAAACCG TTTG 
4 - TGCAGTGATGTGAACGTGGT TTTC 
zDHHC7 
1 - GAAGGCAGCAGCATGACGAA TTTG 
2 - GGTACTGCCCCAGGGTCGGT TTTG 
3 - ATACAGCAGCACTTGGGGCA TTTA 
4 - GCAAATACTGCAGTGGTGGG TTTT 
zDHHC8 
1 - AGGCGCGTCCCGGGGCTGCG TTTG 
2 + TCCTGGCCAACTTCAGCATG TTTG 
3 + ATGGACCCTGGTGTTTTCCC TTTC 
4 + CCCCCGAGCGGATGAGGATG TTTT 
zDHHC9 
1 - CCGGGCCATCATGACGCGGC TTTG 
2 + AGTGCCGCTACCTGGCTGTT TTTG 
3 - TATGAAAGCTGCTTCATCTG TTTC 
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4 - TCTGGAAATTCTTGATACGA TTTA 
zDHHC11 
1 - CATTATTGAGTATGGCTTCT TTTT 
2 + CTCGGCCACCTTCGGGATCT TTTC 
3 - CTTGTTCACGGTGACCTTGC TTTT 
4 + TTGGCTTGGTGCACCTGGGC TTTC 
zDHHC11B 
1 + CTTGGCCACCTTCAGGATCT TTTC 
2 - TTGTTCACGGTGACCTTGCA TTTC 
3 + TCCAGCAAGGAGCTGGCGCC TTTC 
4 - TTGTTGCAGCCCAAGTGTAG TTTC 
zDHHC12 
1 - AGCTCCTCCTGAGGCTGGGG TTTG 
2 + TGGTCTACCTGGCGCTGCAG TTTG 
    
    
zDHHC13 
1 + GTCGATATGGCATCTGTGCA TTTG 
2 + CAAGGTTCTTGGTTGGGTAT TTTC 
3 + CCTGATTTAGCAGGAGCCCC TTTC 
4 + GTACATCATGTCTTATAAGG TTTT 
zDHHC14 
1 - ATGGGCCCGCCGCCGCCGGG TTTC 
2 - ACCGCCAGGTACGGACAGTC TTTC 
3 - GTTCTGGGAGGCGGGCGGTA TTTG 
4 + TGATAACTGCGTAGAACGGT TTTG 
zDHHC15 
1 - CTGCTGGGCTCAAAACAGTC TTTT 
2 - GCTGCTGTGGGAGTGTAAAG TTTG 
3 - GCCATATCAACAAGCATCTG TTTG 
4 - ACACACACATAGCACAGACA TTTA 
zDHHC16 
1 + GGGGCAGTGACACCGCTGTT TTTG 
2 + GAGTGGTGTTCGTGGTCCTG TTTG 
3 + TTCTATAGCCACTGGAATCT TTTC 
4 + CCCCAAGCCAGCCCGAACAC TTTA 
zDHHC17 
1 + ACACCAAGATGGCGGACGGC TTTA 
2 - CTTTGTCCGGTTGCCGTACA TTTT 
3 - CCAAATCAAGCGCTGATTCG TTTG 
4 + ATACGAAAACCGGTGAGGTC TTTG 
zDHHC18 
1 + ACTGTCCCTACCTGGCTCGC TTTG 
2 - TCCAGGGCGGCTGCTTCACA TTTC 
3 + ACACGTACCTCGTCGCCTCC TTTC 
4 + TTCTCTCCCTCTCATTCCTG TTTA 
zDHHC19 
1 + CTGCCTTCAATGTGGTGCTG TTTG 
2 + CTGTTATCACAGGCTCCCTC TTTC 
3 + ACTCAACTTCTCAGACCCTG TTTC 
4 - GACACCATTGCAGGCGGAAG TTTG 
zDHHC20 
1 + TTATGTTTGTATGGTCCTAT TTTG 
2 - ATAACGTTCCTTTTCAGAAT TTTC 
3 + CCTATCTATACCACATCAGC TTTA 
4 + CGTGGCTGCAACAGTTTTAG TTTT 
 106 
zDHHC21 
1 + TTGTTGACCCACATGGTTGG TTTG 
2 + CTCACTATGAAGAAGGACAT TTTC 
3 - TCCATGTGGGATCTTGGGGT TTTC 
4 + ATGAGACCAAAGCGTTCCCA TTTG 
zDHHC22 
1 + TTCACCGGCAACTGCATCGG TTTC 
2 + CATCTCCTTCGCCCACCCCT TTTC 
3 - AGAACCCAGGACAGCTCCGG TTTC 
4 - CGAAGACCTCTTGTAAGTTC TTTC 
zDHHC23 
1 - TTCACAGGCTTCATACTGCC TTTC 
2 - CATGTAATCCATCGATCACA TTTA 
3 + TGATCGCCTCCGAATTCCTT TTTC 
4 - GTGGGGCTTCCAGCTGGCAT TTTG 
zDHHC24 
1 - GCATTGGTAGCAGTAAGCCC TTTG 
2 + CCTTGGCCTTCGTGACGGAC TTTG 
    
    
 
Targeted Control sgRNAs 
 
Gene sgRNA 
# 
Strand Sequence PAM 
hEIF3B 
1 - CTCCCGCGTCCTCGGACACC TTTC 
2 - AGTTTCTCAAGTCGGTCGGG TTTG 
3 + CCTGGAGTACGCGTCCCCTG TTTT 
hDICER1 
1 + GACTGCCATGGCAACAAGAA TTTG 
2 - TCGATAGGGGTGGTCTAGGA TTTC 
3 - ATAAAGCCCACTTCTGTCAG TTTC 
hPOLR2A 
1 - GCAGCGGCCAGTCCGCTCAA TTTG 
2 - GGTTGTTAGAGTCCACAAGC TTTG 
3 - CTTTGGTCAGATCCTCGTCA TTTT 
hNRF1 
1 - GGTCACTCCGTGTTCCTCCA TTTG 
2 + CTTCGGAAACTTCGAGCCAC TTTG 
3 - ACTATGGTCCGTAGTGCCTG TTTA 
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Non-targeted Control sgRNAs 
 
# 0 10 20 30 40 50 
0  
CAAGTTG
GACCGTT
AGCTAT 
GAATCCC
GACGACT
TGTTTG 
GCGCGGG
CCAGACG
GCCTTT 
GCCGGAA
TTGCGCCT
CTCGT 
GGAACCG
GCGATAC
CGAACG 
0
1 
TAAGGCG
CACACCT
CGGATG 
TCCCGTA
GTGGGAT
CGCTCC 
CGATTATC
CTCCACCC
GAGC 
CAGGCCT
TATCGGG
ACTCGA 
GGTATCG
AAATACC
GTAGGC 
GCGGCCG
CGACGTA
TACCGT 
0
2 
AGGCCGG
GCACTGT
AAGTTG 
AGCGGCG
AGATACT
TGCCGG 
GCCGCGG
CTAGGGA
CGGACA 
ACCGAGG
CGCCCCA
CAGTGC 
ACGGGGG
ACGGTCA
CACGCG 
TACCAAA
TCAGAGC
GCGGAC 
0
3 
TCGGTCA
GGCCGTA
CAGGTG 
CGAGTTG
GCTGTACT
AGACG 
CACCGAG
ATCATAC
GGAAAA 
CCGCCCC
CGGAGGT
AATAGT 
ACACCTCT
ACGTGAC
ATAGT 
 
0
4 
TTCGTCCG
CTCAGAG
TCGAC 
GGCGTAA
CTCGAGA
GTGTGT 
GGCCATC
GATCCCG
GCTTAG 
GCGTCGA
CTAATGT
GGAACA 
GCCAACC
TGGCATG
GTTGAC 
 
0
5 
AGCAAGG
CCTATCCG
GCCGT 
AGTGCGG
CCAAGGG
TATTAC 
CCGTTGAC
GCATCAC
CGAGT 
AGAACCT
AGCGGCT
CTCACG 
GCCGCAA
ATCCTTGT
CGGCG 
 
0
6 
GCCCAAG
TTAGCGC
ATAGAG 
ATGCGTA
CGAGGTC
TATGAT 
CCCCGCGT
CGGTCAG
GCCTC 
ACTCGAT
CCACCGT
TAACTA 
GCTTGTGA
CCTGCGCC
ATAG 
 
0
7 
GTCAGCG
GTTATTAC
CGCAA 
GGCGGCG
TCCGGCTT
GAGTC 
ACATTGG
GACGGGT
TAAACT 
TCGAACG
CCACCGG
TCCCTT 
TTACTCGC
GGCTCGG
ACTCG 
 
0
8 
GGGCGCC
GGGGCGT
CCGCGA 
GACCGTG
TCGGAGC
TCGGCC 
TCTCGATC
GCTAACG
TCCCC 
TCAGGGG
CGACTAC
CGTTGT 
GCGTGCC
AACCATA
GAAGCC 
 
0
9 
TACGATA
GGCCGCG
GTCTGC 
GCCAAGC
GATTTTAC
GGTTA 
TACTAGG
CCAGCGA
GACTAA 
TTGCCGTA
TCAGCGA
GGAAG 
GCAGCAC
GGACGAA
ACACGG 
 
 
 
 
